var title_f33_7_33904="Beclomethasone: Drug information";
var content_f33_7_33904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beclomethasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21109?source=see_link\">",
"       Beclomethasone (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30199?source=see_link\">",
"       Beclomethasone (oral inhalation): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9068 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33904=[""].join("\n");
var outline_f33_7_33904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21109?source=related_link\">",
"      Beclomethasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30199?source=related_link\">",
"      Beclomethasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_7_33905="Mucous membrane pemphigoid gingivitis";
var content_f33_7_33905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Desquamative gingivitis with edema and hemorrhage in this patient with mucous membrane pemphigoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33905=[""].join("\n");
var outline_f33_7_33905=null;
var title_f33_7_33906="Intake and void volume record";
var content_f33_7_33906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    24-hour intake and void volume record",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 688px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33906=[""].join("\n");
var outline_f33_7_33906=null;
var title_f33_7_33907="MRI Listeria rhombencephalitis";
var content_f33_7_33907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Brain magnetic resonance imaging of a patient with rhombencephalitis due to Listeria monocytogenes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Axial FLAIR image shows a homogenous hyperintense area in the central portion of the midbrain. The anterior part of the peduncles and the collicular area are spared.",
"    <br>",
"     (B) Axial T1-weighted image following contrast administration shows a nodular area of enhancement with poorly defined margins within the lesion. Note the small anterior satellite nodule (arrow).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Moragas M, Martinez-Yelamos S, Majos C, et al. Rhombencephalitis. Medicine 2011; 90:256. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33907=[""].join("\n");
var outline_f33_7_33907=null;
var title_f33_7_33908="Contracture of burned hand";
var content_f33_7_33908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contractures of the burned hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Syndactyly of the digits can occur following skin grafting of the burned hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33908=[""].join("\n");
var outline_f33_7_33908=null;
var title_f33_7_33909="LUL atelectasis PA";
var content_f33_7_33909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left upper lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PA view of LUL atelectasis due to an endobronchial squamous cell carcinoma. An ill-defined opacity is superimposed on the upper half of the left hemithorax, making it appear denser than the comparable region in the right hemithorax. The trachea is deviated to the left, the left hilum is retracted cephalad, and the left pulmonary artery fills the aortopulmonary window. Vascular branches to the superior segment of the left lower lobe form an array of linear and tubular opacities (ALTO). A vertical lucency separates the aortic arch from the medial margin of the collapsed lobe and forms an air crescent (\"Luftsichel\") (arrow). This finding probably represents an incomplete left major fissure with parts of the lower lobe pulled forward by the upper lobe, which collapses anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33909=[""].join("\n");
var outline_f33_7_33909=null;
var title_f33_7_33910="Bronchiolitis in SLE";
var content_f33_7_33910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis obliterans in SLE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lung biopsy in a patient with systemic lupus erythematosus and bronchiolitis obliterans demonstrating organizing fibroblastic polyps within the alveolar ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33910=[""].join("\n");
var outline_f33_7_33910=null;
var title_f33_7_33911="Antigen in gut";
var content_f33_7_33911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Antigen uptake in the gut",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Antigens may be taken up from the gut lumen by three different cell types. A) Soluble antigen can cross the epithelium via transcellular (endocytosis) or paracellular routes. B) Dendritic cells can extend dendrites into the lumen and sample antigen. C) M cells in Peyer's patches take up particulate antigens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Chehade, M, Mayer, L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005; 115:3. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2005 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33911=[""].join("\n");
var outline_f33_7_33911=null;
var title_f33_7_33912="Frozen shoulder (adhesive capsulitis)";
var content_f33_7_33912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Frozen shoulder (adhesive capsulitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33912/contributors\">",
"     Tore A Prestgaard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33912/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33912/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33912/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/7/33912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frozen shoulder has been defined by the American Academy of Orthopedic Surgeons as: &ldquo;A condition of varying severity characterized by the gradual development of global limitation of active and passive shoulder motion where radiographic findings other than osteopenia are absent.&rdquo; The condition is also characterized by severe shoulder pain.",
"   </p>",
"   <p>",
"    Frozen shoulder is also referred to as adhesive capsulitis, painful stiff shoulder, and periarthritis. We will use the term &ldquo;frozen shoulder&rdquo; throughout this review. This topic will review the diagnosis and management of frozen shoulder. Evaluation of the patient with undifferentiated shoulder pain and other specific causes of shoulder pain or dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50715762\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of frozen shoulder is estimated to be 2 to 5 percent of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The condition is most common in the fifth and sixth decades of life, with the peak age in the mid-50s. Onset before the age of 40 is rare. Women are more often affected than men. The non-dominant shoulder is slightly more likely to be affected. In 6 to 17 percent of patients, the other shoulder becomes affected within five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frozen shoulder occurs predominantly unilaterally and is usually self-limited, with a prolonged course lasting over two to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/4\">",
"     4",
"    </a>",
"    ]. However, some studies have found that up to 40 percent of patients have symptoms and restriction of movement that persist beyond three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/5\">",
"     5",
"    </a>",
"    ], and 15 percent have long-term disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frozen shoulder can be primary (or idiopathic) but is often associated with other diseases and conditions. Patients with diabetes mellitus are at greater risk of developing frozen shoulder, with a prevalence of 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. The condition has also been associated with thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], prolonged immobilization, stroke, autoimmune disease, and in rare instances with Parkinson disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/12\">",
"     12",
"    </a>",
"    ] and antiretroviral therapy (particularly protease inhibitors) for HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More commonly, frozen shoulder is a secondary problem that develops after shoulder injuries, such as rotator cuff tears, proximal humerus fractures, or shoulder surgery. It has also been reported subsequent to other surgical procedures, such as cardiac surgery and neurosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology of frozen shoulder is not fully understood. A common hypothesis is based upon arthroscopic observations that inflammation occurs initially, especially in and around the axillary fold of the joint capsule, followed by the development of adhesions and fibrosis of the synovial lining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/17\">",
"     17",
"    </a>",
"    ]. In part, the process involves thickening and contraction of the glenohumeral joint capsule and the collagenous tissue surrounding the joint, thereby markedly reducing joint volume.",
"   </p>",
"   <p>",
"    Despite these observations, disagreement exists about whether the underlying pathologic process is primarily an inflammatory or fibrosing condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/18\">",
"     18",
"    </a>",
"    ], or perhaps even an algoneurodystrophic process (ie, related to sympathetic dystrophy or complex regional pain syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The disease seems to affect particularly the anterosuperior joint capsule, the coracohumeral ligament, and the rotator cuff interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of stroke, the pathologic condition may differ from idiopathic frozen shoulder: stiffness may result from muscle spasticity and glenohumeral subluxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frozen shoulder is commonly described as progressing through three phases:",
"   </p>",
"   <p>",
"    1. An initial, painful phase with development of diffuse, severe, and disabling shoulder pain that is worse at night, and increasing stiffness that lasts for two to nine months.",
"   </p>",
"   <p>",
"    2. An intermediate phase with stiffness and severe loss of shoulder motion, but with pain becoming gradually less pronounced, that lasts for 4 to 12 months.",
"   </p>",
"   <p>",
"    3. A recovery phase with a gradual return of range of motion that takes from 5 to 24 months to complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical for patients with frozen shoulder are complaints of severe, nagging pain at night and progressive global stiffness of the shoulder, with significant disability restricting activities of daily living, work, and leisure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Later in the course, as stiffness and severe loss of shoulder motion come to predominate, pain persists, particularly at the outer limits of shoulder movement. The varying degrees of impaired function associated with frozen shoulder can include limited reaching (eg, overhead, to the side, across the chest) and limited rotation (eg, unable to scratch the back, put on a coat).",
"   </p>",
"   <p>",
"    Although there are few formal studies of factors that might affect the stages described above, our clinical experience is that the duration of these stages is consistent among the range of causes of frozen shoulder. In other words, the time needed for recovery does not differ substantially between patients with idiopathic or post-traumatic frozen shoulder, or among patients with diabetes, stroke, or other associated medical conditions. Concomitant conditions, such as degenerative disc disease of the cervical spine, can cause discomfort, but they do not appear to influence the duration of symptoms associated with frozen shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568975\">",
"    <span class=\"h1\">",
"     EXAMINATION AND DIAGNOSTIC TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stiff and painful glenohumeral joint makes it difficult to perform a complete shoulder examination. Nevertheless, patients with frozen shoulder usually demonstrate significant reductions in active and passive range of motion in two or more planes compared with their unaffected shoulder. In most cases, external rotation and abduction are the movements most affected. Patients with frozen shoulder often demonstrate difficulties placing their hand on their back or buttock. The shoulder examination is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with frozen shoulder, there is normally less pain with isometric strength testing of shoulder strength. Typically, there is also a firm, painful, and premature end to passive range of motion in a frozen shoulder. This limitation in motion is a true mechanical restriction, rather than a pain-related limitation.",
"   </p>",
"   <p>",
"    The following photographs of a patient with frozen shoulder show common examination findings associated with the condition. Note the differences in motion between the affected left shoulder and the normal right shoulder (",
"    <a class=\"graphic graphic_picture graphicRef68745 \" href=\"mobipreview.htm?17/31/17913\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3796752\">",
"    <span class=\"h2\">",
"     Injection test",
"    </span>",
"    &nbsp;&mdash;&nbsp;An injection test may be helpful in establishing the diagnosis if, following a careful history and physical examination, the clinician continues to have difficulty distinguishing between frozen shoulder and subacromial conditions. In patients with frozen shoulder, active movement restriction and the palpable, painful end detected with passive motion testing persist after injection of an anesthetic into the subacromial space. In contrast, patients with pain from focal subacromial pathology (eg, rotator cuff tendinopathy, subacromial bursitis) generally experience pain relief and improved range of motion. The injection can easily be performed with or without ultrasound guidance and is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link&amp;anchor=H47#H47\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Injection tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Plain radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are of limited diagnostic use in patients with frozen shoulder; most often the plain film is normal, except for osteopenia in some cases. Nevertheless, it is reasonable to obtain routine shoulder x-rays (including posteroanterior, external rotation, Y-outlet, and axillary views) in patients with suspected frozen shoulder to exclude other disorders, such as glenohumeral osteoarthritis, which may present with similar symptoms and clinical findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26630?source=see_link\">",
"     \"Glenohumeral osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) studies are usually not necessary to make the diagnosis of frozen shoulder in patients with a typical history and physical examination, and no evidence of other pathology. However, in diagnostically challenging cases (eg, patients with concomitant glenohumeral osteoarthritis, persistent active rotator cuff tendinopathy, or neurologic deficits affecting the shoulder girdle), MRI or MR arthrography can be helpful. In frozen shoulder, MRI typically shows a thickening of the joint capsule and the coracohumeral ligament.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21217301\">",
"    <span class=\"h3\">",
"     Musculoskeletal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no specific ultrasound findings for frozen shoulder, a sonographic assessment can be helpful. Findings associated with frozen shoulder may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thickening of the coracohumeral ligament and the soft-tissue structures in the rotator cuff interval (in the early phase)",
"      <br/>",
"      <br/>",
"      (The rotator cuff interval is the space between the subscapularis and supraspinatus tendons that contains the long head of the biceps tendon and is used for ultrasound imaging)",
"     </li>",
"     <li>",
"      Increased fluid in the tendon sheath of the long head of the biceps",
"     </li>",
"     <li>",
"      Increased vascularity around the intra-articular portion of the biceps tendon and the coracohumeral ligament (requires color Doppler imaging)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dynamic imaging of patients with frozen shoulder reveals limitations in the sliding movement of the supraspinatus tendon below the acromion during abduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/24\">",
"     24",
"    </a>",
"    ]. Ultrasound is also helpful in ruling out pathology of the rotator cuff and bursa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6775630\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of frozen shoulder is suspected in patients complaining predominantly of unilateral shoulder pain and stiffness, either with spontaneous onset without an underlying cause or subsequent to shoulder surgery or injury (eg, rotator cuff tear, proximal humerus fracture). Remember that patients with diabetes mellitus and other systemic diseases are at increased risk. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology and pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Frozen shoulder is a clinical diagnosis made on the basis of the medical history and physical examination. The diagnosis is confirmed by demonstrating reduced range of motion of the glenohumeral joint that is not due to other painful conditions (eg, glenohumeral osteoarthritis, rotator cuff tendinopathy, subacromial bursitis, fractures). No specific test (laboratory or imaging) alone provides the diagnosis. Plain x-ray, ultrasound, and MRI can be used to rule out other conditions and to confirm the likelihood of the correct diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6775362\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early symptoms and signs of frozen shoulder can be confused with subacromial pathology (eg, rotator cuff tendinopathy, subacromial bursitis, impingement syndrome). In all these conditions, patients report pain and limited active range of motion. However, several facets of the clinical presentation and examination help to distinguish frozen shoulder from these conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with subacromial pathology often give an occupational or athletic history of heavy lifting or repetitive movements, especially above shoulder level. Patients with rotator cuff tendinopathy and subacromial bursitis often complain of activity-related pain and problems performing usual activities. In some cases, symptoms may occur in the non-dominant arm and in non-manual workers.",
"   </p>",
"   <p>",
"    Limitations in shoulder motion are more often due to pain in patients with subacromial pathology, as opposed to the mechanical restrictions found with frozen shoulder, particularly in its later stages. In contrast, patients with a painful subacromial condition demonstrate limited",
"    <strong>",
"     active",
"    </strong>",
"    range of motion while",
"    <strong>",
"     passive",
"    </strong>",
"    range of motion is preserved.",
"   </p>",
"   <p>",
"    Although frozen shoulder may be preceded by a history of subacromial symptoms, patients are just as likely to describe a spontaneous onset without an apparent cause or a history of overuse or abnormal activity. Frozen shoulder can develop following shoulder injuries, surgery, or prolonged immobilization for any reason. Patients with frozen shoulder often complain of chronic, severe, nagging pain deep in the shoulder (ie, glenohumeral) joint, especially at night, and of progressive global stiffness of the shoulder that severely restricts activities of daily living, work, and leisure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age is another distinguishing factor. Frozen shoulder is unlikely in patients younger than 40 years of age, and patients older than 70 are more likely to have rotator cuff tears or glenohumeral osteoarthritis.",
"   </p>",
"   <p>",
"    Later in the course of frozen shoulder, as stiffness and severe loss of motion come to predominate, pain persists, particularly at the outer limits of shoulder movement. The varying degrees of impaired function associated with frozen shoulder include limited reaching (eg, overhead, to the side, across the chest) and limited rotation (eg, unable to scratch the back or put on a jacket).",
"   </p>",
"   <p>",
"    Other problems that occur less often but are included in the differential diagnoses of frozen shoulder include referred pain from the neck or diaphragm, degenerative disc disease of the cervical spine, myocardial ischemia, polymyalgia rheumatica, and malignancy, particularly apical lung cancers and metastases. Clinicians should pay close attention to any patient with systemic symptoms and signs consistent with cancer, infection, or other chronic illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50716276\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, frozen shoulder is a self-limited condition, although complete resolution does not occur in many patients. There is little high quality evidence to guide treatment and consequently no standard management approach exists. Treatment options vary from benign neglect to invasive techniques.",
"   </p>",
"   <p>",
"    Patient education is important to reduce frustration and ensure compliance with treatment.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsteroidal antiinflammatory drugs (NSAID) may be used for pain control. However, there are no randomized controlled trials that confirm the effectiveness of NSAIDs in frozen shoulder. Sometimes, particularly in the early phase of the condition, opioid analgesics may be required.",
"   </p>",
"   <p>",
"    Common nonoperative treatments for frozen shoulder include physical therapy, glucocorticoids given orally or as intra-articular injections, with or without hydrodilatation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8573352\">",
"    <span class=\"h2\">",
"     General approach to management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the treatment of frozen shoulder must be modified based upon patient characteristics and goals, we generally use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial evaluation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obtain a good history. Confirm the diagnosis by demonstrating reduced range of motion of the glenohumeral joint that is not due to other painful conditions. Be certain the cervical spine is not involved. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain plain radiographs of shoulder to rule out other diagnoses as indicated. Perform ultrasound evaluation to rule out rotator cuff pathology. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis is difficult, give an intra-articular injection test of glucocorticoid and anesthetic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      20 to 40 mg and 1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      5 mL). (See",
"      <a class=\"local\" href=\"#H3796752\">",
"       'Injection test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some clinicians give a glucocorticoid injection for moderate to severe symptoms. Some clinicians skilled in the procedure may perform intra-articular dilation as part of the initial treatment. (See",
"      <a class=\"local\" href=\"#H3796802\">",
"       'Glucocorticoid injection'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H13\">",
"       'Intra-articular dilation (distension)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Next two to three months:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Shoulder rest combined with gentle range of motion exercises for the glenohumeral joint, if they do not cause undue discomfort. Photographs of the exercises are provided in the physical therapy discussion. (See",
"      <a class=\"local\" href=\"#H3796784\">",
"       'Physical therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If little or no improvement at follow-up visits (approximately every three weeks): Give glucocorticoid injection. Perform home exercise program as symptoms allow. Video clips of the exercises are provided in the physical therapy discussion. (See",
"      <a class=\"local\" href=\"#H3796784\">",
"       'Physical therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If significant improvement at follow-up visits: Perform more aggressive exercise regimen to increase glenohumeral range of motion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following months: Periodically (approximately every two to three months) reassess range of motion and pain. Most often, patients can perform a more strenuous home exercise program. Refer to physical therapist if needed.",
"     </li>",
"     <li>",
"      Months 10 to 12: Refer to orthopedic surgery if no improvement or severe restrictions in glenohumeral movement persist. If there are any signs of improvement, continue with exercises",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physical therapy and reassess.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3796784\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although physical therapy is commonly used to treat frozen shoulder, evidence for its effectiveness is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/25\">",
"     25",
"    </a>",
"    ]. In fact, one prospective study of 77 patients with idiopathic frozen shoulder reported that exercise performed within the limits of pain led to greater improvements in shoulder function than intensive physical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/26\">",
"     26",
"    </a>",
"    ]. More aggressive stretching of the shoulder muscles and capsule may be useful in the later phase of the condition. The addition of supervised physical therapy following glucocorticoid injection may result in more rapid improvement than injection alone. (See",
"    <a class=\"local\" href=\"#H3796815\">",
"     'Glucocorticoid injections combined with physical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with mild disease and those early in the recovery phase of frozen shoulder may benefit from performing gentle range of motion exercises (eg, pendulum swings) provided they do not cause undue discomfort. As pain allows, patients can add stretching and strengthening exercises, with or without the supervision of a physical therapist. In the author&rsquo;s experience, overly aggressive physical therapy performed early in the course of frozen shoulder often produces increased pain with little improvement in shoulder function.",
"   </p>",
"   <p>",
"    The gentle shoulder motion exercises recommended by the author early in the course of frozen shoulder consist of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gentle abduction (",
"      <a class=\"graphic graphic_picture graphicRef83378 \" href=\"mobipreview.htm?19/47/20222\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gentle external rotation (",
"      <a class=\"graphic graphic_picture graphicRef83379 \" href=\"mobipreview.htm?12/36/12878\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gentle internal rotation (",
"      <a class=\"graphic graphic_picture graphicRef83380 \" href=\"mobipreview.htm?11/42/11950\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gentle combined abduction and external rotation (",
"      <a class=\"graphic graphic_picture graphicRef83381 \" href=\"mobipreview.htm?11/9/11423\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercises that can be added as shoulder motion begins to improve include those depicted in the video clips below. The author recommends that patients perform these exercises twice daily.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abduction-adduction with exercise band (",
"      <a class=\"graphic graphic_movie graphicRef83382 \" href=\"mobipreview.htm?12/26/12719\">",
"       movie 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Flexion extension with exercise band (",
"      <a class=\"graphic graphic_movie graphicRef83384 \" href=\"mobipreview.htm?19/21/19792\">",
"       movie 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seated external rotation with elbow resting on table (",
"      <a class=\"graphic graphic_movie graphicRef83385 \" href=\"mobipreview.htm?34/0/34816\">",
"       movie 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3796791\">",
"    <span class=\"h2\">",
"     Oral corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of several small studies of variable quality found that a short course of oral glucocorticoids can reduce pain and improve mobility in patients with frozen shoulder, but relief generally does not extend beyond a few weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/27\">",
"     27",
"    </a>",
"    ]. As an example, a double-blinded controlled trial of 50 patients reported that a three week course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (30 mg daily) produced significant short-term improvements in shoulder pain and function, but the benefits were not maintained beyond six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/28\">",
"     28",
"    </a>",
"    ]. We suggest that oral glucocorticoids",
"    <strong>",
"     not",
"    </strong>",
"    be given as a routine treatment for frozen shoulder given their potential adverse effects and the increased effectiveness of intra-articular glucocorticoid injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3796802\">",
"    <span class=\"h2\">",
"     Glucocorticoid injection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50715931\">",
"    <span class=\"h3\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intra-articular glucocorticoid injections appear to be beneficial in the treatment of frozen shoulder, leading to improved range of motion and pain reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ]. However, the effect is of limited duration. Successful treatment probably depends upon the duration of symptoms: patients who receive injections early in their course are more likely to obtain benefit, possibly due to a reduction of synovitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/7\">",
"     7",
"    </a>",
"    ]. One randomized trial reported a trend toward greater improvements in shoulder function and pain at six weeks in patients (n = 25) treated with a 40 mg intra-articular injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    compared to patients (n = 32) injected with 10 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of trials using multiple glucocorticoid injections, there was evidence that up to three injections was beneficial and limited evidence that up to six injections was beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/32\">",
"     32",
"    </a>",
"    ]. Single versus multiple glucocorticoid injections were not compared in any included study. Adverse reactions included increased pain after injection (10 to 44 percent), facial flushing (12.5 to 20 percent), rash (4 percent), and irregular menstrual bleeding (10.5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21217333\">",
"    <span class=\"h3\">",
"     Accuracy of intra-articular injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic guidance for intra-articular injections is being used more frequently. In a randomized trial of intra-articular injections performed by experienced musculoskeletal clinicians (orthopedists and rheumatologists), unintended extra-articular injections occurred in as many as 50 to 60 percent of the procedures performed without ultrasound guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/33\">",
"     33",
"    </a>",
"    ]. Inaccurate (ie, extra-articular) injections are substantially less effective at reducing pain and improving function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early studies of intra-articular glucocorticoids to treat frozen shoulder primarily involved injections performed using external anatomic landmarks for guidance. Considering the low accuracy of this approach, ultrasound-guided intra-articular injections would likely improve the effectiveness of this treatment for frozen shoulder. Randomized controlled studies to test this hypothesis are underway, as are studies of alternative injection sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3796815\">",
"    <span class=\"h2\">",
"     Glucocorticoid injections combined with physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although evidence is limited, the combination of intra-articular glucocorticoid injection followed by physical therapy may be more effective than either therapy alone for frozen shoulder. This was demonstrated in a trial of 93 patients who were randomly assigned to treatment with glucocorticoid injection followed by physical therapy, glucocorticoid injection alone, saline injection followed by physical therapy, or saline injection (placebo) alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients treated with glucocorticoid injection and physical therapy experienced significantly faster improvements in shoulder function than the other three groups. Of note, physical therapy alone was of limited benefit and by one year there was no discernible difference in improvement among the four groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intra-articular dilation (distension)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another treatment for frozen shoulder is to combine intra-articular injection of an anesthetic with an infusion of saline to dilate the glenohumeral capsule (the technique is referred to as hydrodilatation or arthrographic distension). Essentially, saline is injected into the joint under pressure. This technique is based upon the finding that frozen shoulder generally involves thickening and contraction of the glenohumeral joint capsule and the collagenous tissue surrounding the joint, thereby markedly reducing joint volume, which is felt to contribute to diminished glenohumeral motion.",
"   </p>",
"   <p>",
"    According to a systematic review of five trials including 196 patients, arthrographic distension with saline and glucocorticoid provides short-term benefits in pain reduction, range of motion, and overall shoulder function in patients with frozen shoulder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/37\">",
"     37",
"    </a>",
"    ]. Further study is needed to determine whether this intervention is superior to alternative treatments.",
"   </p>",
"   <p>",
"    Although hydrodilatation appears to be an effective short-term treatment when compared with sham injection (ie, arthrography only), it is less certain that capsular distention plus glucocorticoids is superior to glucocorticoid injection alone. A 2001 meta-analysis, which emphasized the limited nature of the relevant studies, concluded that the available evidence favored hydrodilatation over the use of glucocorticoid injections alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the better studies to address this question was a trial in which 76 patients were randomly assigned to treatment with a glucocorticoid injection plus hydrodilatation or glucocorticoid injection alone, with injections given under fluoroscopic guidance at two-week intervals over a six week period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/39\">",
"     39",
"    </a>",
"    ]. The authors found no significant difference between groups in the degree of improved shoulder function. Other studies comparing treatment with hydrodilatation to glucocorticoid injection alone have noted improvement in both groups without significant differences in outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8573595\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some systematic reviews of treatments for painful shoulder or frozen shoulder include claims that laser therapy provides short-term relief of pain from adhesive capsulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/25,43\">",
"     25,43",
"    </a>",
"    ]. However, the studies cited to support this claim are outdated and involve patients with rotator cuff &ldquo;tendinitis,&rdquo; not frozen shoulder, and thus, are not relevant. There is no high quality evidence that laser therapy is an effective treatment for frozen shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Referral and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment should be reserved for patients who do not respond to conservative management. There is little evidence and no formal guidelines to determine an appropriate timeframe for referral. We think most patients should be managed conservatively for at least one year as long as they are making progress. The referral process should be individualized based upon patient characteristics and goals. Failure of the patient with frozen shoulder to regain full range of motion may stem from underlying comorbidities, such as osteoarthritis of the glenohumeral joint or rotator cuff muscle atrophy, possibly due to a cervical radiculopathy or peripheral nerve pathology.",
"   </p>",
"   <p>",
"    Manipulation of the shoulder under general anaesthesia has proven to be effective; however, it does not allow for a controlled release of pathologic tissue and carries an increased risk of humerus fracture and intra-articular shoulder lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/44\">",
"     44",
"    </a>",
"    ]. Arthroscopic surgical release is now more commonly performed. Arthroscopic techniques include the use of bipolar radiofrequency devices to carry out a controlled capsular release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33912/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6759718\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general treatment scheme, including follow-up, is provided above. (See",
"    <a class=\"local\" href=\"#H8573352\">",
"     'General approach to management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/26/22946?source=see_link\">",
"       \"Patient information: Frozen shoulder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/53/29522?source=see_link\">",
"       \"Patient information: Rotator cuff injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/21/37201?source=see_link\">",
"       \"Patient information: Frozen shoulder (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=see_link\">",
"       \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4000969\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frozen shoulder describes a painful and stiff glenohumeral joint that has lost distensibility of the capsule and range of motion (particularly abduction and external rotation). The condition is either primary (idiopathic), with or without predisposing conditions such as diabetes mellitus, or develops following shoulder trauma, such as a rotator cuff tear, proximal humerus fracture, or shoulder surgery. The condition is self-limited in the great majority of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frozen shoulder is diagnosed clinically on the basis of the history and physical examination. Passive and active ranges of motion are substantially reduced. A subacromial injection test can be useful to distinguish frozen shoulder from subacromial conditions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6775630\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3796752\">",
"       'Injection test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic imaging is generally unnecessary to diagnose frozen shoulder. Plain radiographs of the shoulder can be helpful to rule out other disorders such as glenohumeral osteoarthritis. Ultrasound often reveals characteristic changes in the soft tissues consistent with frozen shoulder and can be used to assess the rotator cuff. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no consensus on the best approach to treatment. Initially, we suggest resting the shoulder and performing gentle shoulder mobility exercises, rather than aggressive physical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). More demanding exercises are added as the patient&rsquo;s symptoms and mobility improve. For patients with moderate to severe symptoms, it is reasonable to give an intra-articular injection of glucocorticoid and anesthetic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      20 to 40 mg and 1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      5 mL). Suggested exercises and a basic management plan are provided in the text. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3796784\">",
"       'Physical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3796802\">",
"       'Glucocorticoid injection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8573352\">",
"       'General approach to management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Truly refractory cases of frozen shoulder can be referred for surgical evaluation. In most cases, surgical referral should be deferred as long as the patient is making progress with nonoperative management. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Referral and surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/1\">",
"      Mor&eacute;n-Hybbinette I, Moritz U, Scherst&eacute;n B. The clinical picture of the painful diabetic shoulder--natural history, social consequences and analysis of concomitant hand syndrome. Acta Med Scand 1987; 221:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/2\">",
"      Reeves B. The natural history of the frozen shoulder syndrome. Scand J Rheumatol 1975; 4:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/3\">",
"      Rizk TE, Pinals RS. Frozen shoulder. Semin Arthritis Rheum 1982; 11:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/4\">",
"      Grey RG. The natural history of \"idiopathic\" frozen shoulder. J Bone Joint Surg Am 1978; 60:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/5\">",
"      SIMMONDS FA. Shoulder pain with particular reference to the frozen shoulder. J Bone Joint Surg Br 1949; 31B:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/6\">",
"      Binder AI, Bulgen DY, Hazleman BL, Roberts S. Frozen shoulder: a long-term prospective study. Ann Rheum Dis 1984; 43:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/7\">",
"      Hazleman BL. The painful stiff shoulder. Rheumatol Phys Med 1972; 11:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/8\">",
"      Lequesne M, Dang N, Bensasson M, Mery C. Increased association of diabetes mellitus with capsulitis of the shoulder and shoulder-hand syndrome. Scand J Rheumatol 1977; 6:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/9\">",
"      Pal B, Anderson J, Dick WC, Griffiths ID. Limitation of joint mobility and shoulder capsulitis in insulin- and non-insulin-dependent diabetes mellitus. Br J Rheumatol 1986; 25:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/10\">",
"      Wohlgethan JR. Frozen shoulder in hyperthyroidism. Arthritis Rheum 1987; 30:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/11\">",
"      Bowman CA, Jeffcoate WJ, Pattrick M, Doherty M. Bilateral adhesive capsulitis, oligoarthritis and proximal myopathy as presentation of hypothyroidism. Br J Rheumatol 1988; 27:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/12\">",
"      Riley D, Lang AE, Blair RD, et al. Frozen shoulder and other shoulder disturbances in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989; 52:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/13\">",
"      Zabraniecki L, Doub A, Mularczyk M, et al. Frozen shoulder: a new delayed complication of protease inhibitor therapy? . Rev Rhum Engl Ed 1998; 65:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/14\">",
"      Peyriere H, Mauboussin JM, Rouanet I, et al. Frozen shoulder in HIV patients treated with indinavir: report of three cases. AIDS 1999; 13:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/15\">",
"      Grasland A, Ziza JM, Raguin G, et al. Adhesive capsulitis of shoulder and treatment with protease inhibitors in patients with human immunodeficiency virus infection: report of 8 cases. J Rheumatol 2000; 27:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/16\">",
"      Bruckner FE, Nye CJ. A prospective study of adhesive capsulitis of the shoulder (\"frozen shoulder') in a high risk population. Q J Med 1981; 50:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/17\">",
"      Neviaser TJ. Adhesive capsulitis. Orthop Clin North Am 1987; 18:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/18\">",
"      Bunker TD, Anthony PP. The pathology of frozen shoulder. A Dupuytren-like disease. J Bone Joint Surg Br 1995; 77:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/19\">",
"      M&uuml;ller LP, M&uuml;ller LA, Happ J, Kerschbaumer F. Frozen shoulder: a sympathetic dystrophy? Arch Orthop Trauma Surg 2000; 120:84.",
"     </a>",
"    </li>",
"    <li>",
"     Hand GC, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder: a chronic inflammation mast cell mediated proliferative fibrosis. 2005 SECEC/ESSSE meeting Rome; 2005 Sep 21-24: Rome, Italy.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/21\">",
"      Ozaki J, Nakagawa Y, Sakurai G, Tamai S. Recalcitrant chronic adhesive capsulitis of the shoulder. Role of contracture of the coracohumeral ligament and rotator interval in pathogenesis and treatment. J Bone Joint Surg Am 1989; 71:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/22\">",
"      Kalichman L, Ratmansky M. Underlying pathology and associated factors of hemiplegic shoulder pain. Am J Phys Med Rehabil 2011; 90:768.",
"     </a>",
"    </li>",
"    <li>",
"     Bianchi, S, Martinoli, C. Shoulder. In: Ultrasound of the musculoskeletal system, Bianchi, S, Martinoli, C (Eds), Berlin, Heidelberg  2007. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/24\">",
"      Ryu KN, Lee SW, Rhee YG, Lim JH. Adhesive capsulitis of the shoulder joint: usefulness of dynamic sonography. J Ultrasound Med 1993; 12:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/25\">",
"      Favejee MM, Huisstede BM, Koes BW. Frozen shoulder: the effectiveness of conservative and surgical interventions--systematic review. Br J Sports Med 2011; 45:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/26\">",
"      Diercks RL, Stevens M. Gentle thawing of the frozen shoulder: a prospective study of supervised neglect versus intensive physical therapy in seventy-seven patients with frozen shoulder syndrome followed up for two years. J Shoulder Elbow Surg 2004; 13:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/27\">",
"      Buchbinder R, Green S, Youd JM, Johnston RV. Oral steroids for adhesive capsulitis. Cochrane Database Syst Rev 2006; :CD006189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/28\">",
"      Buchbinder R, Hoving JL, Green S, et al. Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial. Ann Rheum Dis 2004; 63:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/29\">",
"      Lorbach O, Anagnostakos K, Scherf C, et al. Nonoperative management of adhesive capsulitis of the shoulder: oral cortisone application versus intra-articular cortisone injections. J Shoulder Elbow Surg 2010; 19:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/30\">",
"      Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003; :CD004016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/31\">",
"      de Jong BA, Dahmen R, Hogeweg JA, Marti RK. Intra-articular triamcinolone acetonide injection in patients with capsulitis of the shoulder: a comparative study of two dose regimens. Clin Rehabil 1998; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/32\">",
"      Shah N, Lewis M. Shoulder adhesive capsulitis: systematic review of randomised trials using multiple corticosteroid injections. Br J Gen Pract 2007; 57:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/33\">",
"      Sibbitt WL Jr, Peisajovich A, Michael AA, et al. Does sonographic needle guidance affect the clinical outcome of intraarticular injections? J Rheumatol 2009; 36:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/34\">",
"      Eustace JA, Brophy DP, Gibney RP, et al. Comparison of the accuracy of steroid placement with clinical outcome in patients with shoulder symptoms. Ann Rheum Dis 1997; 56:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/35\">",
"      Lee HJ, Lim KB, Kim DY, Lee KT. Randomized controlled trial for efficacy of intra-articular injection for adhesive capsulitis: ultrasonography-guided versus blind technique. Arch Phys Med Rehabil 2009; 90:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/36\">",
"      Carette S, Moffet H, Tardif J, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum 2003; 48:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/37\">",
"      Buchbinder R, Green S, Youd JM, et al. Arthrographic distension for adhesive capsulitis (frozen shoulder). Cochrane Database Syst Rev 2008; :CD007005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/38\">",
"      Alvado A, P&eacute;lissier J, B&eacute;naim C, et al. [Physical therapy of frozen shoulder: literature review]. Ann Readapt Med Phys 2001; 44:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/39\">",
"      Tveit&aring; EK, Tariq R, Sesseng S, et al. Hydrodilatation, corticosteroids and adhesive capsulitis: a randomized controlled trial. BMC Musculoskelet Disord 2008; 9:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/40\">",
"      Jacobs LG, Barton MA, Wallace WA, et al. Intra-articular distension and steroids in the management of capsulitis of the shoulder. BMJ 1991; 302:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/41\">",
"      Corbeil V, Dussault RG, Leduc BE, Fleury J. [Adhesive capsulitis of the shoulder: a comparative study of arthrography with intra-articular corticotherapy and with or without capsular distension]. Can Assoc Radiol J 1992; 43:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/42\">",
"      Gam AN, Schydlowsky P, Rossel I, et al. Treatment of \"frozen shoulder\" with distension and glucorticoid compared with glucorticoid alone. A randomised controlled trial. Scand J Rheumatol 1998; 27:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/43\">",
"      Green S, Buchbinder R, Hetrick S. Physiotherapy interventions for shoulder pain. Cochrane Database Syst Rev 2003; :CD004258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/44\">",
"      Hamdan TA, Al-Essa KA. Manipulation under anaesthesia for the treatment of frozen shoulder. Int Orthop 2003; 27:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33912/abstract/45\">",
"      Berghs BM, Sole-Molins X, Bunker TD. Arthroscopic release of adhesive capsulitis. J Shoulder Elbow Surg 2004; 13:180.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 225 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33912=[""].join("\n");
var outline_f33_7_33912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4000969\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50715762\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568975\">",
"      EXAMINATION AND DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3796752\">",
"      Injection test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Plain radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21217301\">",
"      - Musculoskeletal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6775630\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6775362\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50716276\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8573352\">",
"      General approach to management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3796784\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3796791\">",
"      Oral corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3796802\">",
"      Glucocorticoid injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50715931\">",
"      - Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21217333\">",
"      - Accuracy of intra-articular injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3796815\">",
"      Glucocorticoid injections combined with physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intra-articular dilation (distension)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8573595\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Referral and surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759718\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4000969\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/225|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/31/17913\" title=\"picture 1\">",
"      Frozen shoulder motion restrictions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/47/20222\" title=\"picture 2\">",
"      Abduction exercise for frozen shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/36/12878\" title=\"picture 3\">",
"      External rotation exercise for frozen shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/42/11950\" title=\"picture 4\">",
"      Internal rotation exercise for frozen shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/9/11423\" title=\"picture 5\">",
"      Abduction external rotation exercise for frozen shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/225|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?12/26/12719\" title=\"movie 1\">",
"      Abduction adduction exercise for frozen shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?19/21/19792\" title=\"movie 2\">",
"      Active flexion extension exercise for frozen shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?34/0/34816\" title=\"movie 3\">",
"      Seated external rotation exercise for frozen shoulder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26630?source=related_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/21/37201?source=related_link\">",
"      Patient information: Frozen shoulder (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/26/22946?source=related_link\">",
"      Patient information: Frozen shoulder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=related_link\">",
"      Physical examination of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_7_33913="Periventricular leukomalacia";
var content_f33_7_33913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Periventricular leukomalacia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     Kimiko Deguchi, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     Geoffrey Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33913/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/7/33913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periventricular leukomalacia (PVL) refers to injury of cerebral white matter that occurs in a characteristic distribution and consists of periventricular focal necrosis, with subsequent cystic formation, and more diffuse cerebral white matter injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/1\">",
"     1",
"    </a>",
"    ]. PVL is the major form of brain white matter injury that affects premature infants, and is associated with the subsequent development of cerebral palsy, intellectual impairment, and visual disturbances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, pathophysiology, pathology, diagnosis, and management of PVL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lesions of PVL were described more than 100 years ago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/2\">",
"     2",
"    </a>",
"    ]. Parrot recognized the periventricular lesions as infarcts called 'cerebral st&eacute;atose' [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/3\">",
"     3",
"    </a>",
"    ]. Banker and Larroche used the term 'periventricular leukomalacia', described the neuropathological changes that corresponded to coagulation necrosis, and defined the clinicopathological correlations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PVL is more common in premature than term infants, and occurs more frequently with decreasing gestational age and size. The greatest period of risk for PVL is under 32 weeks of gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/5\">",
"     5",
"    </a>",
"    ]. PVL also occurs in late preterm and term infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/6\">",
"     6",
"    </a>",
"    ]. In the United States, infants born at less than 32 weeks account for about 2 percent of all live births, and very low-birth-weight infants (&lt;1500 g) account for about 1 percent of all live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=see_link&amp;anchor=H3#H3\">",
"     \"Incidence and mortality of the premature infant\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of PVL varies among centers and between survivors and nonsurvivors. The use of different ultrasonographic criteria (eg, echodensities or echolucencies) or MRI criteria contributes to this variability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of PVL based upon ultrasonographic findings ranges from 5 to 15 percent in very low-birth-weight infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/8\">",
"       8",
"      </a>",
"      ]. In one study that evaluated the outcomes in approximately 4600 infants with birth weight &lt;1500 g, PVL occurred in 6 percent of those who had sonograms at more than two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/8\">",
"       8",
"      </a>",
"      ]. The incidence declined from 7 to 4 percent in the smallest (501 to 750 g) to largest (1251 to 1500 g) infants.",
"     </li>",
"     <li>",
"      The incidence of PVL based upon MRI findings is variable but generally higher than data based upon ultrasonography, as MRI is more sensitive than ultrasound for the detection of noncystic PVL in premature infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Neuropathologic evidence of PVL is found in 25 to 75 percent of very low-birth-weight infants who die [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/1\">",
"       1",
"      </a>",
"      ]. The incidence increases with longer postnatal survival. Infants who survived more than six days had higher rates of PVL than those who died earlier (60 versus 7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/10\">",
"       10",
"      </a>",
"      ]. Differences between living and autopsied infants occur in part because ultrasonography detects only overt forms of white matter injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prenatal PVL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among infants with PVL who die shortly after birth, the leukomalacia may have developed prenatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Many fetuses who die in utero after 20 weeks gestation have ischemic lesions that are associated with placental abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21929?source=see_link\">",
"     \"Placental pathology in cases of neurologically impaired infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, neuroimaging studies have detected PVL in many children with mild diplegia or hemiplegia who had uneventful term deliveries and neonatal periods, suggesting that the injury occurred prenatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PVL can be caused by ischemia or infection. Because of changes in vascular and cellular factors during development, the brain is more vulnerable to these insults in premature than term infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/1,5,18\">",
"     1,5,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there are numerous animal models for prenatal and perinatal ischemic brain injuries, and while each model partially recapitulates human pathology, none of them fully mimic PVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vascular anatomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the developing cerebral vasculature renders the premature infant especially vulnerable to periventricular white matter injury. Incomplete development of vessels that penetrate the deep and subcortical white matter and those that supply the area near the ventricles result in a boundary zone around the ventricles with diminished vascularization. This area is therefore vulnerable to reduced flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Circulatory factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulatory factors that increase vulnerability to PVL include impaired cerebral vascular autoregulation and vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Autoregulation is needed to maintain adequate cerebral blood pressure despite systemic blood pressure variation, and impairment of autoregulation can result in reduced cerebral perfusion when systemic hypotension occurs.",
"   </p>",
"   <p>",
"    Causes of impaired autoregulation include asphyxia, hypoxemia, hypocarbia, hypotension, excessive handling, and multiple gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/1,15-17\">",
"     1,15-17",
"    </a>",
"    ]. Hypoxemia and hypocarbia also cause cerebral vasoconstriction, decreasing cerebral blood flow. Prenatal circulatory disturbances can cause PVL in the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cellular factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cystic PVL, which occurs predominantly in deep white matter, necrotic changes usually affect all cell components. In contrast, the pathology in diffuse noncystic PVL predominantly affects a specific cell lineage, that of oligodendrocytes.",
"   </p>",
"   <p>",
"    The following observations from cell culture, animal model, and human development studies suggest that oligodendroglial (OL) cells are a particularly susceptible target:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In cell culture, differentiating preoligodendrocytes (preOLs), in contrast with astrocytes, are vulnerable to death induced by the excitatory amino acid glutamate, which increases after ischemic injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/22\">",
"       22",
"      </a>",
"      ]. Furthermore, cultured preOLs are sensitive to the toxic effect of cystine deprivation, a form of oxidative stress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a rodent model of neonatal hypoxia-ischemia, late preOLs but not early or mature OLs are selectively vulnerable to hypoxia-ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In developing human brains, late preOLs are the predominant form during the developmental window of vulnerability for PVL (23 to 32 gestational weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, selective cell death of late preOLs occurs in the diffuse lesion of PVL, which is mediated by oxidative stress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sources of the oxidative stress are attributed to cerebral ischemia and reperfusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/18,29\">",
"     18,29",
"    </a>",
"    ]. Expression of inducible nitric oxide synthase, a key enzyme in the production of nitric oxide, is increased in brains with PVL, suggesting an important role of nitrosative stress in the pathology of PVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/30\">",
"     30",
"    </a>",
"    ]. Ischemic insults result in excessive extracellular levels of glutamate released from damaged axons, reactive astrocytes, and preOLs. Excessive glutamate leads to prolonged depolarization of AMPA and kainate receptors on preOLs, resulting in an influx of calcium into the cells, accumulation of reactive oxygen species, and cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/31\">",
"     31",
"    </a>",
"    ]. Evidence of N-methyl-D-aspartic acid glutamate receptors on preOLs also suggests the presence of an alternative signaling pathway for preOL cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Axonal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axonal maturation studies suggest that axons may be particularly susceptible to damage at a time in development that coincides with the highest risk of PVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Beta amyloid precursor protein, a marker for axonal damage, has been identified in swollen axons around PVL lesions in the white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. One potential mechanism of ischemic axonal injury in PVL is that of N-methyl-D-aspartic acid (NMDA) glutamate receptor excitotoxicity. In support, a study using a cultured rat optic nerve found that damage to small premyelinated axons during oxygen-glucose deprivation required activation of NMDA receptors expressed on oligodendrocyte processes at sites of contact with the small premyelinated axons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antenatal factors increase the risk of premature birth and PVL. As an example, PVL occurs more frequently in premature infants born to mothers with chorioamnionitis, premature or prolonged rupture of the membranes, bacterial vaginosis, or antepartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/11,38-43\">",
"     11,38-43",
"    </a>",
"    ]. In a meta-analysis, chorioamnionitis was associated with cystic PVL (relative risk 3.0) and cerebral palsy (relative risk 1.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/44\">",
"     44",
"    </a>",
"    ]. Funisitis (inflammation of the umbilical cord) or neonatal sepsis also increases the risk of PVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/38,45\">",
"     38,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21929?source=see_link\">",
"     \"Placental pathology in cases of neurologically impaired infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection may be associated with PVL because the white matter is especially susceptible to damage mediated by cytokines produced as a consequence of maternal or fetal infection, even when the infection is asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/41,43,46,47\">",
"     41,43,46,47",
"    </a>",
"    ]. Increased cytokines activate astrocytes and microglia in the white matter, which in turn release reactive oxygen species that result in injury to preOLs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a series of 94 preterm pregnancies in which amniocentesis was performed, 23 newborns had subsequent sonographic evidence of PVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/46\">",
"     46",
"    </a>",
"    ]. Median amniotic fluid concentrations of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 were higher in newborns with PVL than those without. All eight infants who later developed cerebral palsy had PVL and elevated amniotic fluid cytokine levels. In another study, overproduction of tumor necrosis factor-alpha was identified in the microglia of PVL lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammatory cytokines also may play a role in the development of white matter damage during or after ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/41,47\">",
"     41,47",
"    </a>",
"    ]. In another study, preterm infants &le;32 weeks gestational age with genetic variation in the promoter region of the gene encoding interleukin-6 (CC genotype rather than GC or GG), possibly leading to enhanced IL-6 production, were at increased risk for PVL, intraventricular hemorrhage, and hemorrhagic infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/49\">",
"     49",
"    </a>",
"    ]. This functional polymorphism in the IL-6 gene also conveys susceptibility to cerebral palsy among term and near-term infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although PVL is not considered a genetic disease, individual genetic variations, either in the maternal or fetal genome, may contribute to a susceptibility to preterm birth and white matter injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/49,51,52\">",
"     49,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PVL consists of periventricular focal necrosis, with subsequent cystic formation, and more diffuse cerebral white matter injury. Pathological changes in PVL include variable cell damage followed by cystic change, reduction in white matter, and ventriculomegaly. Ischemic injury initially results in focal necrosis with coagulative changes. These changes are followed by axonal swelling and proliferation of microglial cells, macrophages, and reactive astrocytes. The earliest microscopic changes, found within a few days, include astrocyte proliferation and microglia and macrophage accumulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/4\">",
"     4",
"    </a>",
"    ]. Lesions may become cystic or hemorrhagic, with reduced white matter volume and ventriculomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical correlation with pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic changes of PVL are associated with characteristic neurologic deficits. Damage to oligodendroglial cells can impair the myelination of projection and association fibers or interfere with cortical neuronal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic type of PVL with focal necrosis and cyst formation in deep white matter is more common in premature infants with gestational age between 24 to 32 weeks at birth. It is related to the development of cerebral palsy (CP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, a more diffuse cerebral white matter injury occurs in surviving smaller infants (less than 28 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/35\">",
"     35",
"    </a>",
"    ]. Their neurologic outcome is predominated by cognitive impairment, and they are less likely to manifest the typical spastic diplegia CP syndrome at school age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of childhood survivors (mean age 5.6 years) who were born prematurely with PVL, brain MRI using volumetric and diffusion tensor imaging measurements revealed atrophy with abnormal microstructure of the thalamus when compared with 74 term control children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/58\">",
"     58",
"    </a>",
"    ]. The authors speculated that the thalamus contributes to the cognitive deficits frequently observed in children with PVL.",
"   </p>",
"   <p>",
"    Infants born with a very low birth weight (&le;1500 g) are particularly prone to brain injury that involves PVL associated with",
"    <span class=\"nowrap\">",
"     \"neuronal/axonal",
"    </span>",
"    disease\". The latter is a frequent accompaniment of PVL that is characterized by degeneration and volume loss of neurons and axons in the brainstem, basal ganglia, thalamus, cerebral cortex,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebellum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/59\">",
"     59",
"    </a>",
"    ]. The constellation of PVL and",
"    <span class=\"nowrap\">",
"     neuronal/axonal",
"    </span>",
"    disease has been termed \"encephalopathy of prematurity.\" Common sequelae include cognitive, behavioral, attentional, or socialization deficits, while cerebral palsy (major motor deficits) is a less frequent outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periventricular leukomalacia (PVL) is detected in newborns by brain imaging using ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). Ultrasound is the initial standard method because it is portable and least expensive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound findings in PVL consist of echodensities and cysts, but the criteria for diagnosis are not well defined. A standard examination includes coronal and sagittal views. In the coronal view, echodensities typically are seen adjacent to the external angles of the lateral ventricles and distributed throughout the periventricular region. In the parasagittal view, echodensities are apparent at the level of the foramen of Monro and trigone of the lateral ventricles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultrasound findings evolve on repeated examinations. After one to three weeks, approximately one-half of the echodensities evolve into multiple small echolucent cysts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54442 \" href=\"mobipreview.htm?34/18/35111\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55257 \" href=\"mobipreview.htm?12/26/12707\">",
"     image 2",
"    </a>",
"    ). The cysts commonly disappear after one to three months, and ventriculomegaly results. Detection of developing PVL during the first week using power and pulse wave Doppler ultrasound to estimate fluctuations of cerebral blood flow is under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound has limited sensitivity and specificity to detect PVL, especially if the lesions are less than 0.5 cm. Sonograms may detect only 30 to 40 percent of lesions identified at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. This incidence is illustrated by a study in which ultrasound identified only 11 of 39 hemispheres with histological evidence of hypoxic ischemic injury (sensitivity 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/65\">",
"     65",
"    </a>",
"    ]. Serial ultrasound examination and the use of brain MRI improve detection.",
"   </p>",
"   <p>",
"    In addition, while serial cranial ultrasound can detect cystic PVL, it has poor sensitivity for the detection of noncystic PVL. Brain MRI is the imaging modality of choice for the detection of diffuse noncystic PVL. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With the increasing survival rate of extremely preterm infants, the noncystic form of PVL has become important in the current neonatal care of preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Routine ultrasound screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;A practice parameter on neuroimaging of the neonate by the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society made the following recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine ultrasound screening should be performed on all infants with a gestational age less than 30 weeks",
"     </li>",
"     <li>",
"      Screening should be performed at 7 to 14 days of age and repeated at 36 to 40 weeks postmenstrual age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This strategy is designed to detect clinically unsuspected intraventricular hemorrhage (IVH) that may influence monitoring and management, as well as PVL or ventriculomegaly, which provides information about neurodevelopmental outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our practice is more inclusive, although we screen at similar intervals. We recommend routine cranial ultrasonography of all infants born before 33 weeks gestation or with birth weight &lt;1500 g to identify intracranial abnormalities. Infants are screened at 7 to 14 days to detect intraventricular hemorrhage; an initial scan is obtained at three to five days in extremely low-birth-weight infants at high risk for abnormalities. PVL may not be seen on the initial scan. A sonogram performed at 4 weeks of age detects most cystic PVL and ventriculomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. We also obtain a sonogram prior to discharge.",
"   </p>",
"   <p>",
"    If abnormalities are detected by ultrasonography, more frequent examinations are performed to assess the progression of PVL. In this case, MRI frequently is used for better documentation of the extent of white matter injury. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scanning is less useful for the diagnosis of PVL in the very preterm infant because it detects fewer lesions than does MRI or ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/70\">",
"     70",
"    </a>",
"    ]. The reduced sensitivity of CT scanning is due in part to the difficulty in differentiating periventricular hypodensities from areas of hypodensity that normally are present. However, in older infants, CT can identify the loss of periventricular white matter and ventricular enlargement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technological advances have enabled MRI to be performed on preterm infants. PVL is seen as hypointense periventricular lesions on T1-weighted MRI images and as hyperintensity on T2-weighted images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/71\">",
"     71",
"    </a>",
"    ]. Such changes can be detected early in the neonatal stage, even before cystic formation becomes evident on ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI can detect the same well-defined pathologic lesions seen by ultrasound, including IVH and cystic PVL, with the additional advantage of detecting more subtle abnormalities, such as noncystic diffuse white matter injuries, with higher sensitivity. This advantage of MRI is important because noncystic diffuse white matter injuries are common in extremely preterm infants. Comparative studies in preterm infants revealed that cranial ultrasound showed high reliability in the detection of cystic PVL, germinal layer hemorrhage, and IVH, but had significant limitations in the detection of noncystic PVL or diffuse white matter injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. In addition, normal echogenicity in white matter on ultrasound does not always predict normal white matter signal intensity on MRI.",
"   </p>",
"   <p>",
"    Diffusion-weighted imaging (DWI) is an MR technique that demonstrates motion of water in tissue and enables detection of abnormalities in white matter, providing a mechanistic insight into the imaging studies of preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/71,75,76\">",
"     71,75,76",
"    </a>",
"    ]. DWI enables earlier detection of PVL or white matter injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DWI studies show that diffuse high signal intensities seen on T2-weighted MRI, whose interpretation was uncertain, likely represent oligodendrocyte or axonal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. These findings suggest that diffuse high T2 signal intensity in white matter may be a neuroradiologic correlate of the pathologic findings associated with noncystic PVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     MRI in older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older children with spastic cerebral palsy, MRI findings include increased periventricular intensity on T2-weighted scans, ventriculomegaly, a bumpy configuration of the lateral ventricles, high-intensity areas in the white matter adjacent to the trigone body of the lateral ventricles, and deep cortical sulci. These findings result from glial scarring and inadequate myelination of periventricular axons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. MRI findings in children with PVL are related to clinical outcome. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to ischemia and bacterial infections discussed above, other conditions cause periventricular white matter injury. They include malformations and genetic, metabolic, and infectious insults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/53\">",
"     53",
"    </a>",
"    ]. For example, toxoplasmosis and cytomegalovirus cause periventricular necrotizing lesions accompanied by calcification. PVL must also be distinguished from periventricular hemorrhagic infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Periventricular hemorrhagic infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;PVL is distinct from periventricular hemorrhagic infarction, although the two may coexist in premature infants. PVL is generally symmetric and rarely hemorrhagic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/55\">",
"     55",
"    </a>",
"    ]. In contrast, periventricular hemorrhagic infarction nearly always is unilateral or asymmetric and always is grossly hemorrhagic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/55\">",
"     55",
"    </a>",
"    ]. The pathogenesis of this lesion is uncertain, but probably results from infarction caused by venous obstruction after a germinal matrix-intraventricular hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/55\">",
"     55",
"    </a>",
"    ]. The circulatory disturbance is thought to occur in the subependymal region where the medullary veins drain into the terminal vein, as demonstrated by Doppler ultrasound study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In serial imaging studies, periventricular hemorrhagic infarction evolves into a single large cyst, in contrast with the multiple small cysts seen in PVL. This large cyst usually does not disappear and may become confluent with the lateral ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/55\">",
"     55",
"    </a>",
"    ]. The clinical correlate of hemorrhagic infarction is a spastic hemiparesis or an asymmetric spastic quadriparesis that usually is accompanied by intellectual deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific cure exists for periventricular leukomalacia (PVL). Therapy is directed at teaching caregivers to handle, feed, dress, and toilet their children. Physical therapy also may prevent secondary deformities. However, a randomized controlled trial of 105 infants with abnormal cranial ultrasound scans demonstrated no benefit of early physical therapy (started before clinical abnormalities developed) compared with standard treatment (delayed physical therapy, started when abnormal physical signs became apparent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After discharge, infants with PVL are monitored for the development of sequelae, including spastic cerebral palsy, cognitive impairment, and visual and ocular abnormalities. Parents are trained to identify and ameliorate gross and fine motor deficits and disorders of higher mental function and are supported in the care of a handicapped child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial ultrasound and brain MRI may yield prognostic information in neonates and children with PVL. In addition, a meta-analysis of 51 studies with a total of 481,753 infants found that lower umbilical cord pH is significantly associated with intraventricular hemorrhage or PVL (odds ratio 2.9, 95% CI 2.1-4.1) in addition to other adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ultrasound studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial ultrasound findings and neurodevelopmental examinations in newborns correlate with later clinical outcome. Infants with more extensive white matter injury and persistent ventricular enlargement are more likely to have severe motor and cognitive deficits.",
"   </p>",
"   <p>",
"    The sonographic detection of PVL with cyst formation in the neonatal period correlates with the subsequent development of cerebral palsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 12 studies, 58 percent of 272 infants with periventricular echolucency developed cerebral palsy, compared with 2.6 percent of 655 infants with normal cranial ultrasound scans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/87\">",
"       87",
"      </a>",
"      ]. Similarly, premature infants with abnormal neurodevelopmental examinations were more likely to have cerebral palsy (38 versus 6 percent) or minor neuromotor dysfunction (27 versus 13 percent) at 1 year or older, compared with infants with normal examinations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 127 surviving preterm infants with periventricular echodensities or cyst formation, moderate or severe periventricular echodensities with large cyst formation had a positive and negative predictive value for cerebral palsy of 90 and 93 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/44\">",
"       44",
"      </a>",
"      ]. The contribution of periventricular echodensities without cysts to the development of neurologic sequelae is less well defined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormalities confined to the germinal matrix correlate with hemorrhage and do not predict poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another important determinant of long-term outcome is the presence of periventricular intraparenchymal echodensities that represent hemorrhagic necrosis. One report compared the outcomes in 75 infants with extensive or localized intraparenchymal echodensities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/90\">",
"     90",
"    </a>",
"    ]. Infants with extensive injury were more likely to die (79 versus 38 percent), have motor deficits (100 versus 70 percent), and have poor cognitive outcome (80 versus 57 percent) than those with localized lesions.",
"   </p>",
"   <p>",
"    Although ultrasound has been most conventionally and widely performed to detect PVL in preterm infants, it is less effective in identifying infants who have noncystic PVL. In a study of 1749 infants with extremely low birth weight and normal ultrasound studies, 29 percent had either cerebral palsy or delayed mental development before 2 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/91\">",
"     91",
"    </a>",
"    ]. Considering the increase in survival rate of extremely preterm infants, it would be reasonable to consider MRI to add more prognostic information for such high-risk infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     MRI studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal white matter and gray matter findings on brain MRI at term are predictors of adverse neurodevelopmental outcome, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 167 very preterm infants, moderate to severe cerebral white matter abnormalities on MRI performed at term equivalent (gestational age of 40 weeks) were found in 21 percent, and were associated with the following adverse neurodevelopmental outcomes at a corrected age of 2 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/9\">",
"       9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cognitive delay (odds ratio [OR] 3.6, 95% CI 1.5-8.7)",
"     </li>",
"     <li>",
"      Motor delay (OR 10.3, 95% CI 3.5-30.8)",
"     </li>",
"     <li>",
"      Cerebral palsy (OR 9.6, 95% CI 3.2-28.3)",
"     </li>",
"     <li>",
"      Neurosensory impairment (OR 4.2, 95% CI 1.6-11.3)",
"      <br/>",
"      <br/>",
"      The same study found that gray matter abnormalities on MRI at term equivalent were present in 82 infants (49 percent), and were also significantly associated (but less strongly than white matter abnormalities) with cognitive delay, motor delay, and cerebral palsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar study of 86 prematurely born newborns found that neurodevelopmental outcome among survivors at 18 months was normal, borderline, and abnormal in 59, 26, and 15 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/92\">",
"       92",
"      </a>",
"      ]. Increasing severity of white matter injury, ventriculomegaly, and intraventricular hemorrhage on early MRIs (at median age 32 and 37 weeks post-gestation) were associated with abnormal outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Quantitative MRI studies have found a decreased volume of cortical gray matter in preterm infants at term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/93-96\">",
"     93-96",
"    </a>",
"    ] and later in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/97-100\">",
"     97-100",
"    </a>",
"    ] in comparison with normal term infants. Such abnormalities in neuronal development may be associated with the cognitive dysfunction commonly observed in preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, precise quantification of human brain development demonstrates that cortical surface area grows faster than cortical volume in an allometric scaling relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/101\">",
"     101",
"    </a>",
"    ]. This rate of growth is dose-dependently reduced with earlier interruption of pregnancy and is proportional to the risk of later developmental delay.",
"   </p>",
"   <p>",
"    White matter injuries appear to be a major risk factor for cortical abnormalities in preterm infants. In a volumetric MRI study of 119 preterm infants, those with severe or moderate white matter injury had a 17 percent reduction of cortical gray matter volume, 25 percent reduction of absolute myelinated white mater volume, and a 49 percent increase of absolute cerebrospinal fluid volume compared with infants without white matter injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/94\">",
"     94",
"    </a>",
"    ]. In subsequent studies from the same group, white matter injuries had a greater influence on reduction in gray matter at term than other variables (gender, gestational age, intrauterine growth retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/102\">",
"     102",
"    </a>",
"    ]. In addition, white matter injuries at term appear to be predictive of motor and cognitive impairment at 2 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI findings may also be useful to predict disability in older infants or children. For example, in a study of 30 children 6 to 14 years of age with spastic diplegia, the extent of white matter reduction, severity of ventricular dilatation, involvement of the optic radiation, and thinning of the posterior corpus callosum correlated with full scale and performance IQ, but not with verbal IQ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/103\">",
"     103",
"    </a>",
"    ]. In another series of 31 children with spastic cerebral palsy and PVL, lateral ventricular volumes measured on MRI were larger in those with than without cognitive impairment or in age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/104\">",
"     104",
"    </a>",
"    ]. Ventricular volumes were also greater in children with moderate or severe motor deficits than in those with mild deficits. However, the extent of increased periventricular intensity on T2-weighted scans performed in the neonatal period was not as predictive, correlating somewhat with mental impairment but not with the severity of cerebral palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies to prevent periventricular leukomalacia (PVL) emphasize the maintenance of cerebral perfusion. Systemic hypotension, cerebral vasoconstriction, or conditions that impair cerebrovascular autoregulation should be avoided by correcting abnormalities in blood pressure and blood gases (eg, hypocarbia, hypoxemia).",
"   </p>",
"   <p>",
"    The role of neuroprotective agents in the prevention of PVL is being investigated. Antenatal exposure to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28791?source=see_link\">",
"     betamethasone",
"    </a>",
"    may be associated with a decreased risk of cystic PVL. In a retrospective, observational study of 883 preterm infants, the rate of cystic PVL was lower in infants whose mothers received antenatal betamethasone than in those who received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (adjusted odds ratio 0.3) or no glucocorticoid treatment (adjusted odds ratio 0.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/106\">",
"     106",
"    </a>",
"    ]. Further study is needed to confirm these observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33913/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173512202\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Periventricular leukomalacia (PVL) refers to injury of cerebral white matter that occurs in a characteristic distribution and consists of periventricular focal necrosis, with subsequent cystic formation, and more diffuse cerebral white matter injury. PVL is the major form of brain white matter injury that affects premature infants, and is associated with the subsequent development of cerebral palsy, intellectual impairment, and visual disturbances.",
"     </li>",
"     <li>",
"      PVL is more common in premature than term infants, and occurs more frequently with decreasing gestational age and size. The greatest period of risk for PVL is under 32 weeks of gestational age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PVL can be caused by ischemia or infection. Because of changes in vascular and cellular factors during development, the brain is more vulnerable to these insults in premature than term infants. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PVL consists of periventricular focal necrosis, with subsequent cystic formation, and more diffuse cerebral white matter injury. Pathological changes in PVL include variable cell damage followed by cystic change, reduction in white matter, and ventriculomegaly. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PVL is detected in newborns by brain imaging using ultrasound, cranial CT, or MRI. Ultrasound is the initial standard method because it is portable and least expensive. Ultrasound findings in PVL consist of echodensities and cysts, but the criteria for diagnosis are not well defined. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to ischemia and bacterial infections, other conditions can cause periventricular white matter injury, including malformations and genetic, metabolic, and infectious insults. PVL should be distinguished from periventricular hemorrhagic infarction, although the two may coexist in premature infants. PVL is generally symmetric and rarely hemorrhagic. In contrast, periventricular hemorrhagic infarction nearly always is unilateral or asymmetric and always is grossly hemorrhagic. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific cure exists for PVL. Therapy is directed at teaching caregivers to handle, feed, dress, and toilet their children. Infants with PVL should be monitored for the development of sequelae, including spastic cerebral palsy, cognitive impairment, and visual and ocular abnormalities (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cranial ultrasound and brain MRI may yield prognostic information in neonates and children with PVL. Infants with more extensive white matter injury and persistent ventricular enlargement are more likely to have severe motor and cognitive deficits. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Volpe, JJ. Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001.",
"    </li>",
"    <li>",
"     Little, WJ. Lectures on the nature and treatment of the deformities of the human frame. Longmans, Green, London 1853.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/3\">",
"      Parrot J. Sur la st&eacute;atose visc&eacute;rale par inanition chez le nouveau - n&eacute;. C R Acad Sci (Paris) 1868; 67:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/4\">",
"      BANKER BQ, LARROCHE JC. Periventricular leukomalacia of infancy. A form of neonatal anoxic encephalopathy. Arch Neurol 1962; 7:386.",
"     </a>",
"    </li>",
"    <li>",
"     Graham, DI, Lantons, PI. Greenfield's Neuropathology, Arnold, London 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/6\">",
"      Kinney HC. The near-term (late preterm) human brain and risk for periventricular leukomalacia: a review. Semin Perinatol 2006; 30:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/7\">",
"      Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2005. Natl Vital Stat Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/8\">",
"      Stevenson DK, Wright LL, Lemons JA, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol 1998; 179:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/9\">",
"      Woodward LJ, Anderson PJ, Austin NC, et al. Neonatal MRI to predict neurodevelopmental outcomes in preterm infants. N Engl J Med 2006; 355:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/10\">",
"      Shuman RM, Selednik LJ. Periventricular leukomalacia. A one-year autopsy study. Arch Neurol 1980; 37:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/11\">",
"      Zupan V, Gonzalez P, Lacaze-Masmonteil T, et al. Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol 1996; 38:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/12\">",
"      Bejar R, Wozniak P, Allard M, et al. Antenatal origin of neurologic damage in newborn infants. I. Preterm infants. Am J Obstet Gynecol 1988; 159:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/13\">",
"      Squier M, Keeling JW. The incidence of prenatal brain injury. Neuropathol Appl Neurobiol 1991; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/14\">",
"      Iida K, Takashima S, Takeuchi Y, et al. Neuropathologic study of newborns with prenatal-onset leukomalacia. Pediatr Neurol 1993; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/15\">",
"      Burke CJ, Tannenberg AE. Prenatal brain damage and placental infarction--an autopsy study. Dev Med Child Neurol 1995; 37:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/16\">",
"      Hagberg B, Hagberg G, Olow I, von Wendt L. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr 1996; 85:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/17\">",
"      Kr&auml;geloh-Mann I, Petersen D, Hagberg G, et al. Bilateral spastic cerebral palsy--MRI pathology and origin. Analysis from a representative series of 56 cases. Dev Med Child Neurol 1995; 37:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/18\">",
"      Khwaja O, Volpe JJ. Pathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed 2008; 93:F153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/19\">",
"      Silbereis JC, Huang EJ, Back SA, Rowitch DH. Towards improved animal models of neonatal white matter injury associated with cerebral palsy. Dis Model Mech 2010; 3:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/20\">",
"      Takashima S, Tanaka K. Development of cerebrovascular architecture and its relationship to periventricular leukomalacia. Arch Neurol 1978; 35:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/21\">",
"      Rorke LB. Anatomical features of the developing brain implicated in pathogenesis of hypoxic-ischemic injury. Brain Pathol 1992; 2:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/22\">",
"      Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 1993; 13:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/23\">",
"      Back SA, Gan X, Li Y, et al. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J Neurosci 1998; 18:6241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/24\">",
"      Fern R, M&ouml;ller T. Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop. J Neurosci 2000; 20:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/25\">",
"      Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002; 22:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/26\">",
"      Back SA, Luo NL, Borenstein NS, et al. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 2001; 21:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/27\">",
"      Haynes RL, Folkerth RD, Keefe RJ, et al. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol 2003; 62:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/28\">",
"      Back SA, Luo NL, Mallinson RA, et al. Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol 2005; 58:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/29\">",
"      Haynes RL, Baud O, Li J, et al. Oxidative and nitrative injury in periventricular leukomalacia: a review. Brain Pathol 2005; 15:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/30\">",
"      Haynes RL, Folkerth RD, Trachtenberg FL, et al. Nitrosative stress and inducible nitric oxide synthase expression in periventricular leukomalacia. Acta Neuropathol 2009; 118:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/31\">",
"      Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 2001; 50:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/32\">",
"      K&aacute;rad&oacute;ttir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005; 438:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/33\">",
"      Haynes RL, Borenstein NS, Desilva TM, et al. Axonal development in the cerebral white matter of the human fetus and infant. J Comp Neurol 2005; 484:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/34\">",
"      Alix JJ, Zammit C, Riddle A, et al. Central axons preparing to myelinate are highly sensitivity to ischemic injury. Ann Neurol 2012; 72:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/35\">",
"      Deguchi K, Oguchi K, Takashima S. Characteristic neuropathology of leukomalacia in extremely low birth weight infants. Pediatr Neurol 1997; 16:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/36\">",
"      Arai Y, Deguchi K, Mizuguchi M, Takashima S. Expression of beta-amyloid precursor protein in axons of periventricular leukomalacia brains. Pediatr Neurol 1995; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/37\">",
"      Alix JJ, Fern R. Glutamate receptor-mediated ischemic injury of premyelinated central axons. Ann Neurol 2009; 66:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/38\">",
"      O'Shea TM, Klinepeter KL, Meis PJ, Dillard RG. Intrauterine infection and the risk of cerebral palsy in very low-birthweight infants. Paediatr Perinat Epidemiol 1998; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/39\">",
"      Perlman JM, Risser R, Broyles RS. Bilateral cystic periventricular leukomalacia in the premature infant: associated risk factors. Pediatrics 1996; 97:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/40\">",
"      Spinillo A, Capuzzo E, Cavallini A, et al. Preeclampsia, preterm delivery and infant cerebral palsy. Eur J Obstet Gynecol Reprod Biol 1998; 77:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/41\">",
"      Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/42\">",
"      Dammann O, Kuban KC, Leviton A. Perinatal infection, fetal inflammatory response, white matter damage, and cognitive limitations in children born preterm. Ment Retard Dev Disabil Res Rev 2002; 8:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/43\">",
"      Dammann O, Leviton A. Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. Semin Pediatr Neurol 1998; 5:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/44\">",
"      Pidcock FS, Graziani LJ, Stanley C, et al. Neurosonographic features of periventricular echodensities associated with cerebral palsy in preterm infants. J Pediatr 1990; 116:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/45\">",
"      Ernest JM. Neonatal consequences of preterm PROM. Clin Obstet Gynecol 1998; 41:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/46\">",
"      Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997; 177:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/47\">",
"      Yoon BH, Park CW, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. BJOG 2003; 110 Suppl 20:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/48\">",
"      Deguchi K, Mizuguchi M, Takashima S. Immunohistochemical expression of tumor necrosis factor alpha in neonatal leukomalacia. Pediatr Neurol 1996; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/49\">",
"      Harding DR, Dhamrait S, Whitelaw A, et al. Does interleukin-6 genotype influence cerebral injury or developmental progress after preterm birth? Pediatrics 2004; 114:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/50\">",
"      Wu YW, Croen LA, Torres AR, et al. Interleukin-6 genotype and risk for cerebral palsy in term and near-term infants. Ann Neurol 2009; 66:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/51\">",
"      G&ouml;pel W, Kattner E, Seidenberg J, et al. The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g. J Pediatr 2002; 140:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/52\">",
"      H&auml;rtel C, K&ouml;nig I, K&ouml;ster S, et al. Genetic polymorphisms of hemostasis genes and primary outcome of very low birth weight infants. Pediatrics 2006; 118:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/53\">",
"      Armstrong DL. Preterm periventricular axonal and myelin injury. Semin Perinatol 1993; 17:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/54\">",
"      Folkerth RD. Neuropathologic substrate of cerebral palsy. J Child Neurol 2005; 20:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/55\">",
"      Volpe JJ. Neurologic outcome of prematurity. Arch Neurol 1998; 55:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/56\">",
"      Volpe JJ. Encephalopathy of prematurity includes neuronal abnormalities. Pediatrics 2005; 116:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/57\">",
"      Marlow N, Wolke D, Bracewell MA, et al. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/58\">",
"      Nagasunder AC, Kinney HC, Bl&uuml;ml S, et al. Abnormal microstructure of the atrophic thalamus in preterm survivors with periventricular leukomalacia. AJNR Am J Neuroradiol 2011; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/59\">",
"      Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 2009; 8:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/60\">",
"      Veyrac C, Couture A, Saguintaah M, Baud C. Brain ultrasonography in the premature infant. Pediatr Radiol 2006; 36:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/61\">",
"      Ment LR, Bada HS, Barnes P, et al. Practice parameter: neuroimaging of the neonate: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 58:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/62\">",
"      Volpe JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol 1998; 5:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/63\">",
"      Blankenberg FG, Loh NN, Norbash AM, et al. Impaired cerebrovascular autoregulation after hypoxic-ischemic injury in extremely low-birth-weight neonates: detection with power and pulsed wave Doppler US. Radiology 1997; 205:563.",
"     </a>",
"    </li>",
"    <li>",
"     Papile, LA. Intracranial hemorrhage. In: Neonatal-Perinatal Medicine. Diseases of the Fetus and Infant. Fanaroff, AA, Martin, RJ, (Eds), Mosby Year Book, St. Louis 1997. p.893.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/65\">",
"      Hope PL, Gould SJ, Howard S, et al. Precision of ultrasound diagnosis of pathologically verified lesions in the brains of very preterm infants. Dev Med Child Neurol 1988; 30:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/66\">",
"      Paneth N, Rudelli R, Monte W, et al. White matter necrosis in very low birth weight infants: neuropathologic and ultrasonographic findings in infants surviving six days or longer. J Pediatr 1990; 116:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/67\">",
"      Volpe JJ. Cerebral white matter injury of the premature infant-more common than you think. Pediatrics 2003; 112:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/68\">",
"      Townsend SF, Rumack CM, Thilo EH, et al. Late neurosonographic screening is important to the diagnosis of periventricular leukomalacia and ventricular enlargement in preterm infants. Pediatr Radiol 1999; 29:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/69\">",
"      Perlman JM, Rollins N. Surveillance protocol for the detection of intracranial abnormalities in premature neonates. Arch Pediatr Adolesc Med 2000; 154:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/70\">",
"      Keeney SE, Adcock EW, McArdle CB. Prospective observations of 100 high-risk neonates by high-field (1.5 Tesla) magnetic resonance imaging of the central nervous system. II. Lesions associated with hypoxic-ischemic encephalopathy. Pediatrics 1991; 87:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/71\">",
"      Counsell SJ, Rutherford MA, Cowan FM, Edwards AD. Magnetic resonance imaging of preterm brain injury. Arch Dis Child Fetal Neonatal Ed 2003; 88:F269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/72\">",
"      Sie LT, van der Knaap MS, van Wezel-Meijler G, et al. Early MR features of hypoxic-ischemic brain injury in neonates with periventricular densities on sonograms. AJNR Am J Neuroradiol 2000; 21:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/73\">",
"      Inder TE, Anderson NJ, Spencer C, et al. White matter injury in the premature infant: a comparison between serial cranial sonographic and MR findings at term. AJNR Am J Neuroradiol 2003; 24:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/74\">",
"      Maalouf EF, Duggan PJ, Counsell SJ, et al. Comparison of findings on cranial ultrasound and magnetic resonance imaging in preterm infants. Pediatrics 2001; 107:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/75\">",
"      H&uuml;ppi PS, Murphy B, Maier SE, et al. Microstructural brain development after perinatal cerebral white matter injury assessed by diffusion tensor magnetic resonance imaging. Pediatrics 2001; 107:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/76\">",
"      Counsell SJ, Allsop JM, Harrison MC, et al. Diffusion-weighted imaging of the brain in preterm infants with focal and diffuse white matter abnormality. Pediatrics 2003; 112:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/77\">",
"      Inder T, Huppi PS, Zientara GP, et al. Early detection of periventricular leukomalacia by diffusion-weighted magnetic resonance imaging techniques. J Pediatr 1999; 134:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/78\">",
"      Miller SP, Vigneron DB, Henry RG, et al. Serial quantitative diffusion tensor MRI of the premature brain: development in newborns with and without injury. J Magn Reson Imaging 2002; 16:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/79\">",
"      Counsell SJ, Shen Y, Boardman JP, et al. Axial and radial diffusivity in preterm infants who have diffuse white matter changes on magnetic resonance imaging at term-equivalent age. Pediatrics 2006; 117:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/80\">",
"      Ward P, Counsell S, Allsop J, et al. Reduced fractional anisotropy on diffusion tensor magnetic resonance imaging after hypoxic-ischemic encephalopathy. Pediatrics 2006; 117:e619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/81\">",
"      Kr&auml;geloh-Mann I, Horber V. The role of magnetic resonance imaging in elucidating the pathogenesis of cerebral palsy: a systematic review. Dev Med Child Neurol 2007; 49:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/82\">",
"      Accardo J, Kammann H, Hoon AH Jr. Neuroimaging in cerebral palsy. J Pediatr 2004; 145:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/83\">",
"      Taylor GA. Effect of germinal matrix hemorrhage on terminal vein position and patency. Pediatr Radiol 1995; 25 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/84\">",
"      Weindling AM, Hallam P, Gregg J, et al. A randomized controlled trial of early physiotherapy for high-risk infants. Acta Paediatr 1996; 85:1107.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, G. Cerebral Palsies. In: Static Encephalopathies of Infancy and Childhood, Miller, G, Ramer, JC, (Eds), Raven Press, New York 1992. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/86\">",
"      Malin GL, Morris RK, Khan KS. Strength of association between umbilical cord pH and perinatal and long term outcomes: systematic review and meta-analysis. BMJ 2010; 340:c1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/87\">",
"      Holling EE, Leviton A. Characteristics of cranial ultrasound white-matter echolucencies that predict disability: a review. Dev Med Child Neurol 1999; 41:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/88\">",
"      Allen MC, Capute AJ. Neonatal neurodevelopmental examination as a predictor of neuromotor outcome in premature infants. Pediatrics 1989; 83:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/89\">",
"      Levene MI. Cerebral ultrasound and neurological impairment: telling the future. Arch Dis Child 1990; 65:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/90\">",
"      Guzzetta F, Shackelford GD, Volpe S, et al. Periventricular intraparenchymal echodensities in the premature newborn: critical determinant of neurologic outcome. Pediatrics 1986; 78:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/91\">",
"      Laptook AR, O'Shea TM, Shankaran S, et al. Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. Pediatrics 2005; 115:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/92\">",
"      Miller SP, Ferriero DM, Leonard C, et al. Early brain injury in premature newborns detected with magnetic resonance imaging is associated with adverse early neurodevelopmental outcome. J Pediatr 2005; 147:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/93\">",
"      Inder TE, Huppi PS, Warfield S, et al. Periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term. Ann Neurol 1999; 46:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/94\">",
"      Inder TE, Warfield SK, Wang H, et al. Abnormal cerebral structure is present at term in premature infants. Pediatrics 2005; 115:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/95\">",
"      Ajayi-Obe M, Saeed N, Cowan FM, et al. Reduced development of cerebral cortex in extremely preterm infants. Lancet 2000; 356:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/96\">",
"      Peterson BS, Anderson AW, Ehrenkranz R, et al. Regional brain volumes and their later neurodevelopmental correlates in term and preterm infants. Pediatrics 2003; 111:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/97\">",
"      Peterson BS, Vohr B, Staib LH, et al. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. JAMA 2000; 284:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/98\">",
"      Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/99\">",
"      Nosarti C, Al-Asady MH, Frangou S, et al. Adolescents who were born very preterm have decreased brain volumes. Brain 2002; 125:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/100\">",
"      Martinussen M, Fischl B, Larsson HB, et al. Cerebral cortex thickness in 15-year-old adolescents with low birth weight measured by an automated MRI-based method. Brain 2005; 128:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/101\">",
"      Kapellou O, Counsell SJ, Kennea N, et al. Abnormal cortical development after premature birth shown by altered allometric scaling of brain growth. PLoS Med 2006; 3:e265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/102\">",
"      Thompson DK, Warfield SK, Carlin JB, et al. Perinatal risk factors altering regional brain structure in the preterm infant. Brain 2007; 130:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/103\">",
"      Fedrizzi E, Inverno M, Bruzzone MG, et al. MRI features of cerebral lesions and cognitive functions in preterm spastic diplegic children. Pediatr Neurol 1996; 15:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/104\">",
"      Melhem ER, Hoon AH Jr, Ferrucci JT Jr, et al. Periventricular leukomalacia: relationship between lateral ventricular volume on brain MR images and severity of cognitive and motor impairment. Radiology 2000; 214:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/105\">",
"      Fujimoto S, Togari H, Banno T, et al. Correlation between magnetic resonance imaging and clinical profiles of periventricular leukomalacia. Tohoku J Exp Med 1999; 188:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/106\">",
"      Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33913/abstract/107\">",
"      Fanaroff AA, Hack M. Periventricular leukomalacia--prospects for prevention. N Engl J Med 1999; 341:1229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6187 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33913=[""].join("\n");
var outline_f33_7_33913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H173512202\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prenatal PVL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vascular anatomic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Circulatory factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cellular factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Axonal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical correlation with pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Routine ultrasound screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MRI in older children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Periventricular hemorrhagic infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ultrasound studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MRI studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173512202\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6187|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/18/35111\" title=\"diagnostic image 1\">",
"      Ultrasound white matter cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/26/12707\" title=\"diagnostic image 2\">",
"      Ultrasound early periventricular leukomalacia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21929?source=related_link\">",
"      Placental pathology in cases of neurologically impaired infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_7_33914="Coagulation abnormalities in patients with liver disease";
var content_f33_7_33914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coagulation abnormalities in patients with liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Neeral L Shah, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Patrick G Northup, MD, MHES",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Stephen H Caldwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/7/33914/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/7/33914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5858358\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clotting process is a dynamic, highly interwoven array of multiple processes, which can be viewed as occurring in four phases.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initiation and formation of the platelet plug",
"     </li>",
"     <li>",
"      Propagation of the clotting process by the coagulation cascade",
"     </li>",
"     <li>",
"      Termination of clotting by antithrombotic control mechanisms",
"     </li>",
"     <li>",
"      Removal of the clot by fibrinolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Healthy individuals possess adequate amounts of clotting factors, regulatory proteins, and platelets to achieve optimal clot formation, clot limitation, and dissolution. Patients with liver disease, on the other hand, have a disturbed balance of pro-coagulant and anti-coagulant factors deviating from the normal coagulation cascade, with little in the way of &ldquo;reserve&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities of these coagulation pathways in patients with liver disease will be discussed here. An overview of coagulation and the clinical use of coagulation tests are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525348817\">",
"    <span class=\"h1\">",
"     PROBLEM OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various factors contribute to the abnormalities of coagulation seen in patients with liver disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Increased bleeding risk",
"      </strong>",
"      &mdash; Decreased production of non-endothelial cell-derived coagulation factors (eg, factors II, V, VII, IX, X, XI, XIII) is only one component of the coagulation process that disrupts hemostasis. Thrombocytopenia, altered platelet function, platelet inhibition by nitric oxide, abnormalities of fibrinogen, and decreased thrombin activatable fibrinolysis inhibitor (TAFI) all contribute to an increased bleeding risk.",
"     </li>",
"     <li>",
"      <strong>",
"       Increased thrombotic risk",
"      </strong>",
"      &mdash; Decreased levels of the liver-synthesized natural anticoagulant proteins C and S, decreased antithrombin levels, decreased plasminogen, and elevated levels of endothelial cell-derived factor VIII and von Willebrand factor (vWF) favor thrombosis formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The varying degrees of disruption of these opposing pathways lead to different and potentially changing hemostatic activity for individual patients with cirrhosis. The relative balance or imbalance in these patients is not reflected in conventional indices of coagulation, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT) or INR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/3\">",
"     3",
"    </a>",
"    ]. There is now convincing evidence disproving the common misconception that liver disease patients are &ldquo;auto-anticoagulated&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link&amp;anchor=H7#H7\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'International normalized ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858365\">",
"    <span class=\"h1\">",
"     HYPOCOAGULABILITY IN CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, multiple factors can result in a hypocoagulable state in patients with liver disease. Decreased levels of all liver synthesized pro-coagulant factors, including the vitamin K dependent clotting factors (II, VII, IX, and X) in patients with cirrhosis are widely recognized. In addition, the liver modifies these vitamin K dependent factors for proper physiologic function, a function which may be deranged in patients with vitamin K deficiency as well as in those with hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link&amp;anchor=H8#H8\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'Des-gamma-carboxy prothrombin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\", section on 'Plasma proteins of blood coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other liver-synthesized clotting factors that may contribute to hypocoagulability include fibrinogen, factors V, XI, XII, prekallikrein, kininogen, and plasminogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/6\">",
"     6",
"    </a>",
"    ]. Predicting the occurrence of bleeding based on factor levels or composites of factor activity such as the prothrombin time is difficult, due to the occurrence of counter forces, which favor thrombosis (see below) and the development of super-imposed conditions such as infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/7\">",
"     7",
"    </a>",
"    ]. However, this is only a fraction of the disturbances present in the coagulation pathways in patients with liver disease, as will be discussed immediately below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H21#H21\">",
"     \"Disorders of fibrinogen\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525348894\">",
"    <span class=\"h2\">",
"     Abnormalities of platelet number and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia and platelet-endothelial adhesion dysfunction affect clot formation and contribute to a relative hypocoagulable state, especially because platelet levels are pivotal in the initial coagulation response. The surface phospholipids of platelets provide the platform for factor complexes, amplification, and propagation of clot formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hemostasis\", section on 'Multicomponent complexes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many theories exist regarding the genesis of thrombocytopenia in patients with liver disease. Decreased thrombopoietin (TPO) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/9\">",
"     9",
"    </a>",
"    ], splenic sequestration of platelets due to portal hypertension, auto-antibody destruction of platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/10\">",
"     10",
"    </a>",
"    ], and bone marrow suppression due to underlying liver disease can all contribute to thrombocytopenia. Low levels of TPO measured in patients with cirrhosis resolved after undergoing liver transplantation, reinforcing the role of TPO levels in liver disease thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H21#H21\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platelet dysfunction is also a contributing aspect of decreased clot formation. Defective interactions between platelets and the endothelium result in sub-optimal clot formation that can be corrected by the addition of recombinant factor VIIa in an in vitro model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/11\">",
"     11",
"    </a>",
"    ]. In conditions mimicking intravascular flow, low hematocrit and low platelet counts contributed to decreased adhesion of platelets to endothelial cells, although increased vWF may offset this change in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, patients with liver disease and concomitant renal insufficiency (such as different forms of hepatorenal syndrome) may have platelet dysfunction due to uremia and to changes in vessel wall endothelial function. This is a common and often overlooked aspect of impaired hemostasis in cirrhosis. Effective dialysis in this sense can be sometimes viewed as in effect a hemostatic intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H23#H23\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Uremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombin generation is also directly affected by the platelet count in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/13\">",
"     13",
"    </a>",
"    ]. Consistent with the cell-based model of coagulation, studies of thrombin generation capacity in these patients have demonstrated the importance of platelets in potentiating the clotting cascade, leading ultimately to thrombin (factor IIa) generation, which then converts fibrinogen to fibrin. Platelet levels of around 50,000 to",
"    <span class=\"nowrap\">",
"     60,000/microL",
"    </span>",
"    or more were associated with adequate thrombin production, while levels closer to",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    were associated with optimal thrombin production. Accordingly, platelet transfusions in some cirrhotic patients with significant thrombocytopenia and clinical bleeding may augment thrombin generation in addition to correcting the low platelet count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858372\">",
"    <span class=\"h2\">",
"     Infection and endogenous heparinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of infection in patients with liver disease has been estimated to be as high as 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/14\">",
"     14",
"    </a>",
"    ]. Overt sepsis or low levels of endotoxemia can affect platelet function, production, and adhesion in cirrhotics. Moreover, infection has been associated with increased detection of endogenous heparinoids, probably as a reflection of endothelial dysfunction and associated changes in the endothelial glycocalyx, possibly mediated by infection-related changes in nitric oxide metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glycosaminoglycans (heparinoids) found in the vessel wall are bound by the endothelium and help to maintain hemostatic balance by preventing clot formation and facilitating blood flow within a vessel. Two specific glycosaminoglycans (GAGs), heparan sulphate and dermatan sulphate, have anticoagulant properties similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Increased levels of these proteins, measured by thromboelastography, were found in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/16\">",
"     16",
"    </a>",
"    ], and even higher concentrations were found in subjects with cirrhosis and active bleeding or infection. Further exploration of the effect of infection-related GAGs on coagulation in patients with liver disease is necessary and may guide focused pharmacologic therapies for bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858379\">",
"    <span class=\"h2\">",
"     Hyperfibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of systemic fibrinolysis can be detected in 30 to 46 percent of patients with chronic liver disease and parallels the degree of liver dysfunction. However, clinically evident hyperfibrinolysis is less common and has been estimated to occur in 5 to 10 percent of those with decompensated cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperfibrinolysis overlaps with a condition in cirrhosis that resembles disseminated intravascular coagulation (DIC), called &ldquo;accelerated intravascular coagulation and fibrinolysis (AICF),&rdquo; but it can be evident as a distinct clinical entity with intractable bleeding following puncture wounds or dental extractions, or on occasion without any recognizable trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the lack of readily available means to clearly identify this condition (such as via the use of thromboelastography) impedes the evaluation of hyperfibrinolysis in patients with cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=see_link\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperfibrinolysis promotes premature clot dissolution and interferes with clot formation due to the consumption of clotting factors and decreased platelet aggregation due to the degradation of vWF and fibrinogen platelet receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/18\">",
"     18",
"    </a>",
"    ]. The mechanisms involved hinge on dysregulation of a complex set of interacting factors including tPA (tissue plasminogen activator) and PAI-1 (plasminogen activator inhibitor 1), neither of which is liver synthesized, although both have altered clearance in cirrhosis, and TAFI (thrombin-activatable fibrinolysis inhibitor), which is liver synthesized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperfibrinolysis may play a role in several discrete clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has been implicated as an exacerbating factor in variceal rupture by disrupting the hemostatic plug that forms with primary hemostasis.",
"     </li>",
"     <li>",
"      High fibrinolytic activity in saliva likely potentiates bleeding following dental extractions in patients with cirrhosis and fibrinolysis in other normal body cavities, such as the biliary tree, and urinary bladder could potentiate bleeding from these sites in the setting of cirrhosis.",
"     </li>",
"     <li>",
"      Ascites fluid fibrinolytic activity has been proposed as an initiator of systemic hyperfibrinolysis in cirrhosis due to increased thoracic duct delivery of ascites fluid to the systemic circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During liver transplantation, high levels of tPA in the recipient may result in hyperfibrinolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858386\">",
"    <span class=\"h1\">",
"     HYPERCOAGULABILITY IN CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercoagulability is an increasingly recognized aspect of liver disease. The lack of proper measurement tools to identify those patients who are prone to develop clots, and reliance on clinical endpoints (eg, deep vein thrombosis, portal vein thrombosis) likely lead to an under-estimation of this problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. Based upon the National Hospital Discharge Survey, the prevalence of VTE was 0.6 and 0.9 percent for those with chronic alcoholic liver disease and chronic nonalcoholic liver disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, hospitalized patients with liver disease were found to have a 0.5 percent incidence of deep venous thromboembolism despite a &ldquo;coagulopathic profile&rdquo; by conventional parameters in many of the patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study performed in 73 patients with cirrhosis, in vitro assays indicated significantly increased thrombin generation in subjects with cirrhosis when compared with 38 normal controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of such observations and improved understanding of the pathophysiology of clot formation in liver disease, there is increasing awareness that the old dogma of &ldquo;auto-anticoagulation&rdquo; represented by an elevated INR in patients with cirrhosis is unfounded.",
"   </p>",
"   <p>",
"    The reduction of procoagulant factors in cirrhosis, reflected in a prolonged PT and INR, is offset by decreased levels of anti-coagulant factors (ie, protein C, protein S, anti-thrombin) of potentially equal or greater magnitude, but not measured by conventional parameters such as the PT, INR, or aPTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several endothelium-derived procoagulant factors are increased in cirrhosis, including factor VIII and von Willebrand Factor (vWF). The former, an acute phase reactant, is known to be prothrombotic, while increased levels of vWF favor platelet adhesion. Changes in the latter result from compensatory increased production, decreased levels of a vWF cleaving protein in cirrhotics (ADAMTS13), and an increased presence of vWF on endothelial walls due to a chronic inflammatory state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/28\">",
"     28",
"    </a>",
"    ]. Together, these variables contribute to a new and somewhat precariously rebalanced hemostatic system in cirrhosis, which may tilt in either direction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/29\">",
"     29",
"    </a>",
"    ]. A major clinical challenge is to determine how best to measure this as a guide to optimal management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'ADAMTS13 activity in other conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypercoagulability in cirrhosis can lead to macro- and micro-thrombi production, resulting in various complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Macro-thrombotic complications",
"      </strong>",
"      include portal vein thrombosis, deep vein thrombosis, and pulmonary embolism. These clinical outcomes present complex management dilemmas in patients with cirrhosis. Traditional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -based anticoagulation is titrated to measurements of the INR. However, in patients with liver disease the varying INR values lead to unclear targets. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link&amp;anchor=H7#H7\">",
"       \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'International normalized ratio'",
"      </a>",
"      .) At this time, no clear evidence-based recommendations can be made for managing DVT in patients with cirrhosis and therapy must be individualized. (See",
"      <a class=\"local\" href=\"#H5858556\">",
"       'Venous thromboembolism prophylaxis in hospitalized patients with cirrhosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Potential micro-thrombotic complications",
"      </strong>",
"      of cirrhosis are subtle and typically run a chronic course. Intra-hepatic microthrombi can cause localized ischemia, which leads to scarring and accelerated development of cirrhosis in a process known as parenchymal extinction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/30\">",
"       30",
"      </a>",
"      ]. This is thought to be one of the mechanisms leading to liver atrophy, which contributes to the transition to severely decompensated cirrhosis. Platelet aggregation and activation in these microscopic lesions may also contribute to fibrosis and possibly to thrombocytopenia. A similar process in the lung microvasculature appears to play a role in a serious complication of cirrhosis known as portopulmonary hypertension. The resultant remodeling of the pulmonary vasculature can have important ramifications in transplant eligibility, outcomes and survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/31\">",
"       31",
"      </a>",
"      ]. Whether or not anticoagulation therapy prevents development of these micro-thrombotic conditions remains to be fully evaluated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=see_link\">",
"       \"Portopulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Non-alcoholic fatty liver disease (NAFLD)",
"      </strong>",
"      , which is associated with obesity, insulin resistance, diabetes, and dyslipidemia, presents a unique and problematic intersection of chronic liver disease and thrombotic disorders, including coronary vascular disease. Reduced sensitivity to insulin, increased fatty acid levels forming thromboxane A2, and higher low-density-lipoprotein (LDL) levels all contribute to increased platelet aggregation. Increased plasminogen activator inhibitor-1 (PAI-1) also contributes to hypercoagulability in the metabolic syndrome which is almost a universal finding in patients with NAFLD. These problems complicate management of patients with co-existing nonalcoholic steatohepatitis (NASH)-related cirrhosis and coronary disease, especially when coronary re-vascularization is undertaken in the setting of increased risk of portal hypertensive bleeding. Such patients are among the most clinically challenging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858393\">",
"    <span class=\"h2\">",
"     Portal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broadly speaking, portal vein thrombosis (PVT) can be described in terms of patients with or without cirrhosis, the latter including idiopathic PVT and PVT related to thrombophilic factors. We will restrict our comments to PVT in the setting of cirrhosis in this section. The reader is directed to other sections of UpToDate for discussion of non-cirrhotic PVT as well as the Budd-Chiari syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3993?source=see_link\">",
"     \"Extrahepatic portal vein obstruction (portal vein thrombosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PVT affects about 10 to 20 percent of all patients with cirrhosis, but the prevalence varies with disease severity, being much lower in Child-Pugh A patients and increasing step-wise in Child B and C patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/33\">",
"     33",
"    </a>",
"    ]. Contributing factors include stasis due to portal hypertension, development of hepatocellular cancer (HCC), and sometimes to genetic predisposition to hypercoagulability. To what extent this development reflects relative hypercoagulability due to changes in hemostatic pathways discussed above is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focal left or right branch PVT is relatively more common and often clinically silent, although its development may contribute to overall organ atrophy. Extrahepatic portal vein thrombosis (EPVT) is relatively less common but has increased risk of decompensation due to variceal bleeding or portosystemic shunting. The development of any of these forms warrants a careful examination for hepatocellular carcinoma, while EPVT especially should prompt consideration of a more exhaustive search for additional factors, such as prothrombin gene mutation, factor V Leiden, or a myeloproliferative neoplasm (eg, polycythemia vera), especially if there is mesenteric extension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology of the Budd-Chiari syndrome\", section on 'Myeloproliferative disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology of the Budd-Chiari syndrome\", section on 'Other hypercoagulable states'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23501878\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of non-randomized studies have evaluated the risks and benefits of anticoagulation in cirrhotic patients with PVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In general, such treatment has resulted in partial or complete recanalization in 40 to 80 percent, with minimal anticoagulation-associated bleeding.",
"   </p>",
"   <p>",
"    As an example, in one series of 55 patients with cirrhosis and acute or subacute PVT, anticoagulation resulted in partial or complete recanalization in 8 and 25 patients, respectively, for an overall response rate of 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/35\">",
"     35",
"    </a>",
"    ]. The definition of",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    thrombosis was defined as a newly found absence of flow within six months of previous imaging. Early initiation of anticoagulation was the only factor significantly associated with recanalization; re-thrombosis after complete re-canalization occurred in 38 percent of patients after anticoagulation was stopped. Patients who achieved re-canalization developed less frequent liver-related events (portal hypertension-related bleeding, ascites, hepatic encephalopathy) during follow-up, although this difference was not statistically significant. Five patients (9 percent), a larger percent than in previous studies, developed bleeding complications related to anticoagulation. A platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL",
"    </span>",
"    was the only factor significantly associated with a risk for bleeding. There were no deaths attributable to the use of anticoagulation.",
"   </p>",
"   <p>",
"    Anticoagulation to treat acute or subacute PVT may be considered in limited cases, especially when there is extensive clot burden or the presence of secondary factors such as the prothrombin gene mutation. However, the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio is uncertain due to the risk of portal hypertensive bleeding.",
"   </p>",
"   <p>",
"    Anticoagulation has also reduced post-operative complications in patients awaiting liver transplantation, especially those with extensive clot, although this latter approach remains debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general management of patients with PVT is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3993?source=see_link\">",
"     \"Extrahepatic portal vein obstruction (portal vein thrombosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23501885\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary results are available from a prospective, randomized trial of the safety and efficacy of the low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (4000",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    versus placebo for 12 months) for the prevention of PVT in cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/39\">",
"     39",
"    </a>",
"    ]. During the one-year study period, PVT occurred significantly more often in those taking placebo (6 of 36, 17 percent) than in those taking enoxaparin (zero of 34). No relevant side effects, in particular no hemorrhagic events, were attributed to the use of enoxaparin. Enoxaparin treatment was also associated with a lower number of patients developing hepatic decompensation (53 versus 12 percent), suggesting its use for that indication, as well. The final report of this study is eagerly awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858400\">",
"    <span class=\"h1\">",
"     COAGULOPATHY IN ACUTE LIVER FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulopathy is by definition a key component of the diagnostic criteria of acute liver failure (ALF), which is defined as the development of clinically evident hepatic encephalopathy and laboratory evidence of coagulopathy (usually prolongation of the PT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    INR) within 24 weeks of the new onset of acute liver disease with no history of prior liver abnormalities.",
"   </p>",
"   <p>",
"    Prolongation of the PT and INR in this setting is due to impaired synthesis of key factors measured by the prothrombin time, including especially factors VII and V, which have the shortest half-lives of liver-synthesized procoagulant factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/40\">",
"     40",
"    </a>",
"    ]. The biological half-life of factor V is as long as 36 hours but that of factor VII is only four to six hours (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"mobipreview.htm?9/38/9836\">",
"     table 1",
"    </a>",
"    ). Thus, significant and progressive hepatic necrosis will lead to relatively rapid depletion of these factors and prolongation of the PT and the INR.",
"   </p>",
"   <p>",
"    Whether or not prolongation of the PT and INR in the setting of ALF reflects an increased bleeding risk has not been nearly as well studied as the coagulopathy of cirrhosis. One study followed 51 patients with acute liver",
"    <span class=\"nowrap\">",
"     injury/failure",
"    </span>",
"    who underwent global hemostatic testing via thromboelastography (TEG). Despite a mean INR of 3.4, most patients had preserved hemostasis by TEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/41\">",
"     41",
"    </a>",
"    ]. It was concluded that hemostasis was maintained via a combination of increased clot strength with increasing severity of liver injury, increased factor VIII levels, and a commensurate decline in both pro- and anticoagulant proteins.",
"   </p>",
"   <p>",
"    When present, bleeding is usually limited to capillary and mucosal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/42\">",
"     42",
"    </a>",
"    ]. Although this may be relatively minor, the need for multiple invasive procedures increases the concern regarding iatrogenic bleeding.",
"   </p>",
"   <p>",
"    Because of prolongation of the PT and INR, patients with ALF may be treated with fresh frozen plasma (FFP), especially prior to invasive procedures. However, the utility of this intervention has not been clearly demonstrated. Moreover, high INR values may require a significant volume of FFP (much more than the typical doses of two to four units) to correct the laboratory value. This is likely detrimental because large volumes of plasma may worsen body edema and intracranial hypertension due to the remarkably large volumes of plasma needed to correct the INR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In part because of this, recombinant activated factor VII (rFVIIa) has become a conventional means of correcting the INR especially prior to placement of an intracranial pressure monitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/43\">",
"     43",
"    </a>",
"    ]. With rFVIIa, INR can be seen as reflecting an appropriate rFVIIa dose response, although whether or not this reflects a decreased risk of bleeding in ALF patients remains to be established. As with cirrhosis, very little scrutiny of existing literature is needed to see that this area requires further clinical research to determine which of the various available interventions will improve patient care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=see_link&amp;anchor=H20#H20\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Liver failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Coagulopathy of liver dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858414\">",
"    <span class=\"h1\">",
"     TESTS OF COAGULATION IN LIVER DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858423\">",
"    <span class=\"h2\">",
"     Prothrombin time (PT) and the International Normalized Ratio (INR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prothrombin time (PT) is used to assess the extrinsic pathway of clotting, which consists of tissue factor and factor VII, and coagulation factors in the common pathway (prothrombin (factor II), factors V and X, and fibrinogen). The sensitivity of the PT to reduced activity of the vitamin K-dependent factors within this pathway comprises the rationale for the use of the PT to monitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical use of coagulation tests\", section on 'Prothrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to promote standardization of the PT for monitoring oral anticoagulant therapy, the World Health Organization (WHO) developed an international reference thromboplastin, currently recombinant tissue factor, and recommended that the PT ratio be expressed as the International Normalized Ratio or INR. This allows values of the PT from various locations to be directly compared, as may happen when a patient taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has blood sampled at different laboratories. Because this test was developed to assess dysfunction in vitamin K dependent coagulation factors II, VII, IX, and X during warfarin therapy, rather than in patients with cirrhosis, its extrapolation to the liver disease population is under increasing critical scrutiny [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link&amp;anchor=H7#H7\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'International normalized ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858430\">",
"    <span class=\"h3\">",
"     INR variation in liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major shortcoming of utilizing the INR in patients with liver disease is the wide inter-laboratory variation, which depends at least in part on the type of thromboplastin used in the test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/46\">",
"     46",
"    </a>",
"    ]. This degree of variation can have substantial clinical implications in assessing bleeding risk, and in calculating the patient&rsquo;s MELD score (model of end stage liver disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/47\">",
"     47",
"    </a>",
"    ]. The MELD score is calculated from three components, total bilirubin, creatinine, and the INR, and since 2002 it has become the standard score used to list and prioritize patients for liver transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reagent-dependent INR can lead to drastically different MELD scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. As a result of these issues, there have been attempts to develop an alternative form of the INR based on a standard of patients with liver disease, the &ldquo;INR liver&rdquo;, as well as calls to dispense with the INR in patients with cirrhosis and use instead the prothrombin time as a measure of percentage of normal activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/46,52\">",
"     46,52",
"    </a>",
"    ]. A more practical use of this measurement is still being investigated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858437\">",
"    <span class=\"h2\">",
"     Platelet level and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platelet count, which is often included in a complete blood count (CBC), is the quantitative measurement of circulating platelets. It is often depressed in cirrhosis due to the combination of hypersplenism (",
"    <a class=\"graphic graphic_figure graphicRef52400 \" href=\"mobipreview.htm?7/24/7566\">",
"     figure 1",
"    </a>",
"    ), bone marrow depression, and changes in thrombopoietin metabolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H28#H28\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Extravascular nonimmune hemolysis due to hypersplenism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Along with the INR, platelet levels have been a long standing convention in assessing cirrhosis-related bleeding risk. However, in contrast to empiric cut-offs for the INR, more reliable in vitro data exist to support specific levels of circulating platelets as more effectively promoting hemostasis in cirrhosis. Using an assay that resembles in vivo thrombin (factor II) generation, adequate thrombin production was demonstrated with platelet counts of around",
"    <span class=\"nowrap\">",
"     56,000/microL",
"    </span>",
"    and optimal thrombin production at levels closer to",
"    <span class=\"nowrap\">",
"     100,000/microL.",
"    </span>",
"    These findings support the relevance of traditional targets for low-moderate risk procedures and high-risk procedures.",
"   </p>",
"   <p>",
"    However, in cirrhosis, platelet function remains an inadequately addressed aspect of platelet activity in the context of the cell-based mechanism of hemostasis (see above). Different methods of measuring platelet aggregation are available. Commercial tests designed to mimic in vivo hemostasis include the Clot Signature Analyzer, the Thrombotic Status Analyzer, and the Platelet Function Analyzer. All of these modalities measure platelet plug formation within capillary tubes designed to mimic vessels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, none of these tests of platelet function has undergone adequate translational testing to understand the relevance to bleeding in patients with cirrhosis. Such studies are essential to determine this aspect of platelet function in cirrhosis. Increased circulating vWF and systemic changes in cell membrane phospholipid composition upon which the essential elements of the clotting cascade occur are necessary to know whether or not aggregation and activity are impaired or possibly enhanced in cirrhosis. Renal failure (hepatorenal syndrome) and uremic platelet dysfunction is another important but understudied aspect of reduced platelet function in cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H20#H20\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Acquired platelet functional disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858444\">",
"    <span class=\"h3\">",
"     Bleeding time in cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bleeding time is an indirect measure of platelet function. It is variably reported as being prolonged in cirrhosis. The variable results in cirrhosis may reflect counteracting forces, including not only platelet number and activity but also factors such as vascular smooth muscle dysfunction as seen in the &ldquo;hyperdynamic state&rdquo; (diffuse vasodilation) in people with portal hypertension and secondary portosystemic shunting. Test results and the range of normal values are very user dependent, which further lessens its predictive value. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link&amp;anchor=H13#H13\">",
"     \"Platelet function testing\", section on 'The in vivo bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective shortening of the bleeding time with DDAVP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    ) has been demonstrated in cirrhosis (see below). A related measure called the &ldquo;liver bleeding time&rdquo; has also been reported in a number of studies that examined the relationship between liver surface bleeding and peripheral indices of hemostasis following laparoscopic biopsy and in studies of procoagulant factor administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858451\">",
"    <span class=\"h2\">",
"     Fibrinogen and individual factor levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of individual factor levels is sometimes useful clinically.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factor VIII levels may help to distinguish superimposed disseminated intravascular coagulation (DIC) from liver failure. The former is characterized by severely decreased factor VIII levels, while the latter is associated with significantly increased levels.",
"     </li>",
"     <li>",
"      Factor V and VII levels are used prognostically in acute liver failure and may help to distinguish vitamin K deficiency from liver failure. Proportional reduction in both factors suggests liver failure, whereas a greater reduction in factor VII than in factor V favors vitamin K deficiency.",
"     </li>",
"     <li>",
"      Fibrinogen levels can help guide use of fibrinogen-rich cryoprecipitate, as levels below 120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      are associated with diminished clot formation and possibly to resistance to procoagulants such as recombinant factor VIIa.",
"     </li>",
"     <li>",
"      The ratio of factor VIII to protein C may help to identify patients with well preserved thrombin production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/29\">",
"       29",
"      </a>",
"      ]. Individual values of protein C and S as well as antithrombin, sometimes measured in the setting of deep vein thrombosis or portal vein thrombosis, can be difficult to interpret in cirrhosis and requires consideration of relative declines in each of the factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858458\">",
"    <span class=\"h2\">",
"     Fibrin degradation products and D-dimer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased fibrinolytic activity, decreased coagulation factors and decreased platelets can be a component of cirrhosis or coexisting disseminated intravascular coagulation (DIC). The overlap in laboratory abnormalities for cirrhosis and DIC makes these entities sometimes difficult to differentiate. In patients with stable liver disease, levels of thrombin generation, fibrin degradation products (FDP), D-dimer levels, and prothrombin fragments were found to be similar to normal controls, resulting in less overlap with the findings in DIC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in decompensated liver disease, many of these values may mirror those found in DIC. While DIC and liver disease both cause elevations in D-dimer levels, low levels of factor VIII may suggest a predominance of DIC. High D-dimer levels, low factor VIII levels, and end organ micro-thrombotic disease should significantly raise the suspicion of DIC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858465\">",
"    <span class=\"h2\">",
"     Fibrinogen abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of",
"    <strong>",
"    </strong>",
"    the fibrinogen molecule can cause an inherited or acquired coagulation disorder. In cirrhosis, acquired dysfibrinogenemia results in a prolonged thrombin time in the setting of normal fibrinogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dysfibrinogen produced in this setting resembles fetal fibrinogen and presumably reflects the liver&rsquo;s response to injury and the formation of regenerating nodules in the cirrhotic liver. The laboratory diagnosis of dysfibrinogenemia involves tests that are not widely available (eg, fibrin clot formation, thrombin time, reptilase time, and fibrinogen clotting activity-antigen ratio). The significance of dysfibrinogenemia in liver disease has not been fully established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H21#H21\">",
"     \"Disorders of fibrinogen\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3539444\">",
"    <span class=\"h2\">",
"     Thrombin generation testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the many problems associated with the use of standard coagulation tests (ie, PT, aPTT) to evaluate hemostasis in general, including in patients with liver disease, is that they only measure part of the process of thrombin generation. The conventional clotting times typically measure the time it takes from the initiation of clotting to the initial generation of trace amounts of thrombin, ie, the lag time in the thrombin generation curve. It does not take into account the rate of the subsequent burst of thrombin generation, the peak thrombin concentration achieved, the total amount of thrombin formed (the endogenous thrombin potential), and the eventual inhibition of thrombin by the natural anticoagulants. Thus, a number of key factors are not taken into account, such as the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/3\">",
"     3",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of hemostasis\", section on 'Thrombin generation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of hemostasis\", section on 'Activated protein C and protein S'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelets, which support thrombin generation by assembling activated coagulation factors on their surface",
"     </li>",
"     <li>",
"      Thrombomodulin, a protein situated on vascular endothelial cells, which is the main physiologic activator of protein C, a strong inhibitor of thrombin generation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, the addition of platelets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombomodulin to the reaction mixture in thrombin generation tests has been able to indicate the important function of these other factors in contributing to the coagulation imbalance noted in patients with liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/3,4,13,26,29\">",
"     3,4,13,26,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5858437\">",
"     'Platelet level and function'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858472\">",
"    <span class=\"h2\">",
"     Thromboelastography and thromboelastometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally developed over 50 years ago, there has been renewed interest in these tests as functional measures of clot formation and stability in whole blood samples from cirrhosis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/57\">",
"     57",
"    </a>",
"    ]. Although point of care testing may offer the greatest advantage, citrated samples with subsequent recalcification allow a delay in assay performance for one to two hours after collection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thromboelastography (TEG) involves the measurement of torque on a pin as a cup containing whole blood is rotated at a constant rate. As clot formation begins, the torque increases, and then with clot breakdown from fibrinolysis, the torque decreases (",
"      <a class=\"graphic graphic_figure graphicRef51767 \" href=\"mobipreview.htm?16/37/16991\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Thromboelastometry (ROTEM) is similar to the TEG but involves a stationary cup and rotating pin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both assays detect dynamic aspects of clot formation and lysis. Parameters include initiation time, the rate of rise in clot strength, maximal clot strength, and the rate of clot decline as lysis ensues. An overall measurement calculated from these variables gives a coagulation index and a measure of clot stability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23242?source=see_link&amp;anchor=H3046566855#H3046566855\">",
"     \"Coagulopathy associated with trauma\", section on 'Thromboelastography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link&amp;anchor=H24#H24\">",
"     \"Platelet function testing\", section on 'Instruments measuring physical properties of the clot'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, the use of clot stability as measured by the TEG with conventional measures of platelets and INR correlated to blood product use in patients with cirrhosis better than conventional measures alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858479\">",
"    <span class=\"h2\">",
"     Sonorheometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel method of using ultrasound to measure whole blood coagulation is currently being investigated. While TEG employs changes in torque to measure clot formation, sonorheometry utilizes acoustic radiation forces to assess hemostasis. This technique is currently under preliminary investigation, and has not been applied to patients with liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858486\">",
"    <span class=\"h1\">",
"     THERAPEUTIC AGENTS FOR BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proper use of blood products and their efficacy have not been established in patients with liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/60\">",
"     60",
"    </a>",
"    ]. It is still relatively controversial due to the increased risk of transfusion related injury, unwanted volume expansion and associated increases in portal pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], unnecessary cost of blood typing and administration of the infusion, in addition to the cost of the blood products themselves. Nevertheless, with very few alternatives, the focused use of blood products in the proper clinical scenario is one of the only options currently available for the patient with liver disease and bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858493\">",
"    <span class=\"h2\">",
"     Vitamin K",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition in patients with liver disease or cholestatic disease can lead to Vitamin K deficiency, although this can be difficult to diagnose in the setting of cirrhosis-related alterations in coagulation. Vitamin K deficiency is more likely in primary cholestatic diseases such as primary biliary cirrhosis and primary sclerosing cholangitis. The relative decline in factor V versus factor VII is sometimes helpful in questionable cases, since a proportionally greater decline in factor VII than in factor V suggests vitamin K deficiency. If suspected, repletion of vitamin K (dose range: 1 to 25 mg) can be accomplished by oral, subcutaneous, or intravenous administration. Because of edema and possible gut malabsorption in severely jaundiced patients, the intravenous route is sometimes preferred, although this can be associated with anaphylactic reactions. Overcorrection, which may be clinically important in patients being treated with a vitamin K antagonist for thrombotic illnesses, is generally not an issue, but balancing procoagulant activity with thrombotic risk in bedbound patients is challenging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=see_link\">",
"     \"Overview of vitamin K\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858500\">",
"    <span class=\"h2\">",
"     Fresh frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fresh frozen plasma (FFP) is often used to treat coagulopathy in patients with liver disease, its benefit is still unclear. As an example, when 80 such patients were studied, conventional doses of FFP reduced their prothrombin time (PT) to within three seconds of normal in only 10 to 12 percent of recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/64\">",
"     64",
"    </a>",
"    ]. Moreover the amount of plasma needed to more consistently reduce the PT (10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    is the recommended full dose) clearly exposes patients to an increased risk of volume overload (leading to increased portal pressures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/2,61-63\">",
"     2,61-63",
"    </a>",
"    ], as well as transfusion-related injury lung injury (TRALI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/65\">",
"     65",
"    </a>",
"    ]. Furthermore, as mentioned above, it is unclear if the target PT or INR is a true reflection of bleeding risk in those with cirrhosis. Thus, because of uncertainty on the risk-benefit ratio in cirrhosis, these products should be used with caution. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858507\">",
"    <span class=\"h2\">",
"     Cryoprecipitate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoprecipitate contains the cold-insoluble residue that remains when FFP is thawed to a temperature of 4&deg;C. It contains fibronectin, fibrinogen, and von-Willebrand factor (vWF) in a volume-reduced solution. Although it is understudied, there is a general consensus that in the setting of cirrhotic bleeding, fibrinogen levels should be measured and repleted if low. As a rationale, proponents indicate fibrinogen&rsquo;s role as the last step toward fibrin clot formation in the clotting cascade.",
"   </p>",
"   <p>",
"    The optimal fibrinogen level is uncertain, but a level of at least of 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    has been suggested. Surprisingly, many patients maintain a fibrinogen level higher than this even with advanced disease, although the",
"    <strong>",
"     quality",
"    </strong>",
"    of the fibrinogen (ie, the presence or absence of dysfibrinogenemia) is often unmeasured. (See",
"    <a class=\"local\" href=\"#H5858465\">",
"     'Fibrinogen abnormalities'",
"    </a>",
"    above.) Recommended dosing is one bag of cryoprecipitate per 10 kg of body weight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858514\">",
"    <span class=\"h2\">",
"     Platelet transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, transfusions of platelets result in an immediate increase in the platelet counts, maximal at about one hour after completion of the transfusion. In stable non-refractory patients, six units of pooled platelets or one unit of apheresis platelets should raise the platelet levels by about",
"    <span class=\"nowrap\">",
"     30,000/microL,",
"    </span>",
"    although this is highly variable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H558395714#H558395714\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'TTP-HUS, HIT, and DIC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cirrhosis usually demonstrate a blunted response due to splenic sequestration, and the optimal target for platelet therapy in cirrhosis has not been agreed upon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/1\">",
"     1",
"    </a>",
"    ]. In vitro, studies have shown adequate thrombin production with platelet levels from",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and optimal levels at platelet levels closer to",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/13\">",
"     13",
"    </a>",
"    ]. From these data, it is reasonable to aim for levels above",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    for moderate risk procedures (eg, liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/66\">",
"     66",
"    </a>",
"    ]) and above",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    for high risk procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858521\">",
"    <span class=\"h2\">",
"     Recombinant factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have examined the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    (rFVIIa) in liver disease patients, but no conclusive guidelines have been established. rFVIIa rapidly normalizes elevated prothrombin times in cirrhotic patients, but the efficacy in reducing bleeding risk remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/68\">",
"     68",
"    </a>",
"    ]. Depending on the dose, the effect on INR is evident for at least one to two hours. The most common use of rFVIIa in patients with liver disease is in the setting of intracranial pressure (ICP) monitor placement in acute liver failure, where a dose of 40",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    is usually employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Coagulopathy of liver dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link&amp;anchor=H166750581#H166750581\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Bleeding prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantages of rFVIIa include low volume, relative safety, and rapid correction of the",
"    <span class=\"nowrap\">",
"     PT/INR.",
"    </span>",
"    The major disadvantage is overall cost of this product and the possibility of inducing a hypercoagulable state. Since rFVIIa does not have a clearly defined role, it should be reserved for rescue therapy in active hemorrhage or as prophylaxis in very high risk invasive procedures such as ICP monitor placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858528\">",
"    <span class=\"h2\">",
"     Anti-fibrinolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-fibrinolytics prevent clot lysis and are most useful in the setting of hyperfibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/70\">",
"     70",
"    </a>",
"    ]. The hyperfibrinolytic states are difficult to diagnose with conventional testing, and should be considered especially in the setting of delayed bleeding following a procedure or intractable oozing from a puncture wound. Bodily fluids such as ascites or saliva have increased fibrinolytic properties. Therefore in the setting of patients with cirrhosis and bleeding from peritoneal sources or dental extractions, anti-fibrinolytics should be considered.",
"   </p>",
"   <p>",
"    Currently, there are no randomized clinical trials showing any benefit of anti-fibrinolytics in patients with cirrhosis and upper gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/71\">",
"     71",
"    </a>",
"    ]. However, in certain settings, especially when hyperfibrinolysis is proven or suspected, these agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ) may be effective and appear safe in cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/18,20,72,73\">",
"     18,20,72,73",
"    </a>",
"    ]. Dosing of anti-fibrinolytic agents varies among various studies, and most populations consisted of patients without liver disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"       Aminocaproic acid",
"      </a>",
"      loading dose ranges from 1 to 15 g (usually given intravenously at a dose of 4 to 5 g for the first hour followed by 1",
"      <span class=\"nowrap\">",
"       g/hr",
"      </span>",
"      for up to eight hours) and a maximal total dose of 30 g. For dental procedures, aminocaproic acid can be given as a 10 mL (4 g) oral rinse solution that is held in the mouth for 2 minutes and then spit out, repeated every six hours for up to two days or added to a gauze pad as a local compress.",
"     </li>",
"     <li>",
"      Intravenous tranexamic is administered with a 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      loading dose and repeated 3 to",
"      <span class=\"nowrap\">",
"       4/day",
"      </span>",
"      for a total of 2 to 8 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858535\">",
"    <span class=\"h2\">",
"     Prothrombin complex concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prothrombin complex concentrates (PCCs) contain human-derived concentrated vitamin K-dependent factors usually including factors II, IX, and X and variable amounts of factor VII in their inactive forms along with (in some preparations) the natural anticoagulant factors such as protein C and protein S. These agents are often used to reverse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated bleeding, such as warfarin-associated intracerebral hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Unactivated prothrombin-complex concentrates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, very little data exist regarding the efficacy of PCCs in cirrhosis-related bleeding, although the theoretical advantage of a markedly lower infused volume have stimulated interest as substitutes for fresh frozen plasma in active bleeding. Studies are currently planned to study their role in liver disease patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=see_link&amp;anchor=H14#H14\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Prothrombin complex concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858542\">",
"    <span class=\"h2\">",
"     Desmopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an analogue of the antidiuretic hormone vasopressin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) increases levels of factor VIII and vWF, although the exact mechanism for its potential use in cirrhosis is uncertain, as both of these factors are usually elevated. Nonetheless, intravenous doses of 0.3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    in patients with cirrhosis improve bleeding times with little demonstrable effect on systemic hemodynamics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. The use of intranasal dDAVP (300 mcg) was compared with blood product transfusions in patients with cirrhosis undergoing dental extractions. DDAVP had comparable results to infusion of fresh frozen plasma or platelets, but was felt to be more convenient, better tolerated, and less expensive compared with the use of blood products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/77\">",
"     77",
"    </a>",
"    ]. Side effects are usually mild, but may include increases in blood pressure, facial flushing, headache, and hyponatremia. Further studies are needed to clarify the exact role of dDAVP for prophylaxis in patients with liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525349129\">",
"    <span class=\"h2\">",
"     Blood product usage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a lack of evidence-based guidelines regarding optimal use of blood products in patients with liver disease. Based on understanding of the pathophysiology of coagulation in cirrhosis and the limitations of conventional risk indices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/45\">",
"     45",
"    </a>",
"    ], it is likely that blood products are overused in this population, with resultant unnecessary risk exposure.",
"   </p>",
"   <p>",
"    A single center study showed that on three separate days, patients with liver disease consistently utilized one-third of the total fresh frozen plasma infused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/78\">",
"     78",
"    </a>",
"    ]. The disproportionate use of blood products in this group reinforces the need for further clinical studies to help develop evidence-based guidelines for appropriate resource utilization of blood products. Non-evidence based societal guidelines regarding specific cut-offs for conventional tests such as INR should be discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858549\">",
"    <span class=\"h2\">",
"     Renal support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal support therapy (ie, dialysis) has a complex relationship to hemostatic pathways in cirrhosis. There is little doubt that effective dialysis can potentiate platelet function and improve volume status in severe renal failure complicating decompensated cirrhosis, although definitive data such as pre- and post-dialysis thromboelastography are lacking. However, the mechanical aspects of renal replacement therapy can also lead to platelet activation through turbulence and shear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/67\">",
"     67",
"    </a>",
"    ]. The formation of thrombin and glycoprotein receptor activation can initiate the coagulation cascade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequent platelet aggregation may dictate the need for anticoagulation during dialysis. Conversely, platelet destruction during the contact time with bioartificial membranes and increased turnover when in contact with dialysis tubing can lead to worsening of the patient&rsquo;s thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858556\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about peripheral (non-portal) venous thromboembolic events (VTE) in patients with cirrhosis and there have been no randomized controlled trials for the treatment or prophylaxis of deep vein thrombosis (DVT) or pulmonary embolism (PE) in patients with cirrhosis. In fact, all patients with underlying coagulopathy were excluded in the landmark clinical trials studying VTE so there is an extreme paucity of data from which to draw conclusions.",
"   </p>",
"   <p>",
"    As stated above, there are a growing number of single center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/24,79,80\">",
"     24,79,80",
"    </a>",
"    ] and population-based [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/81\">",
"     81",
"    </a>",
"    ] studies showing a prevalence of DVT or PE in hospitalized patients with cirrhosis between 0.5 to 6.3 percent, which is in the range commonly expected in the general internal medicine population. (See",
"    <a class=\"local\" href=\"#H5858386\">",
"     'Hypercoagulability in cirrhosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Acquired thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is clear that patients with cirrhosis are exposed to many risk factors for VTE including cancer, older age, surgical procedures, prolonged hospitalization, and inactivity. Improvements in the treatment of liver disease over the recent decades have led to an increased life expectancy in these patients and thus led to an increased exposure to these risk factors. There is also increasing awareness that the coagulopathy of liver disease is not protective from VTE in patients with cirrhosis.",
"   </p>",
"   <p>",
"    The most obvious fear regarding VTE prophylaxis or treatment in patients with cirrhosis is hemorrhage, especially variceal bleeding from the associated portal hypertension. This is a reasonable concern in the patient admitted with clinical bleeding or with high risk esophageal varices but less clear in the patient with no or low risk varices. Based on the general internal medicine literature and practice, the current clinical practice in many hospitals with experience in treating patients with cirrhosis is to use VTE prophylaxis in those with minimal varices and no evidence of clinical bleeding, especially those with high risk VTE conditions.",
"   </p>",
"   <p>",
"    A study reported in abstract form compared GI bleeding and mortality rates in 235 cirrhotic patients receiving VTE prophylaxis and 141 cirrhotic untreated controls. GI bleeding rates were similar between the treated and control groups (2.54 versus 4.96 percent, respectively), with no significant difference in hospital death rates (3.94 versus 10.64 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of anti-Xa levels as a means of monitoring prophylaxis with low molecular weight (LMW)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and similar agents is under study in some centers, and there is preliminary work showing its shortcomings in liver disease patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H36#H36\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Anti-factor Xa testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data are conflicting as to the significance of low levels of liver-derived antithrombin (AT, previously called antithrombin III) in patients with cirrhosis. Whether these patients are resistant to, or more sensitive to, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is unclear at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. With questions regarding the validity of anti-Xa levels and the conflicting evidence regarding LMW heparin, further studies are needed to answer this question.",
"   </p>",
"   <p>",
"    Lower extremity compression devices have not been studied in patients with cirrhosis and are likely to be of little benefit in the patient with massive peripheral edema. Further clinical studies are needed in this area. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H12#H12\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858563\">",
"    <span class=\"h2\">",
"     Anti-platelet and anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic anticoagulation is occasionally needed in patients with cirrhosis and coagulopathy although the management of therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be difficult because of the baseline coagulopathy as measured by the INR. The best indicator of therapeutic anticoagulation levels in patients with cirrhosis is probably measurement of anti-Factor Xa activity following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    products. However, as noted above, low levels of antithrombin may cause resistance to heparin-like agents.",
"   </p>",
"   <p>",
"    While the safety of therapeutic anticoagulation in patients with decompensated cirrhosis has not been determined, some conclusions can be drawn from sparse data related to anticoagulation in those with acute and chronic portal vein thrombosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study in non-cirrhotic portal hypertension (including esophageal varices) showed good recanalization rates and no excess bleeding events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study in 39 patients with cirrhosis and chronic portal vein thrombosis including 50 percent who presented with variceal bleeding showed a 75 percent complete restoration of portal venous flow using therapeutic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      after complete eradication of varices by band ligation and no significant bleeding complications in the treatment group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study showed an overall survival benefit with therapeutic anticoagulation in patients with splanchnic venous thrombosis awaiting liver transplantation without excess bleeding complication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the total number of patients in these reports is small, the safety of therapeutic anticoagulation in selected patients with cirrhosis but without high risk esophageal varices appears comparable to other general medical patients. Finally, as mentioned above, intrahepatic thrombosis may play a role in parenchymal extinction leading to liver atrophy in cirrhosis. Studies are under consideration to determine the possible utility of low dose anticoagulation or platelet inhibition in stable cirrhosis patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    use in the previously described abstract to prevent PVT also showed a decrease in the occurrence of hepatic decompensation in cirrhotic patients; more studies will be necessary to validate this clinical finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/7/33914/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23501885\">",
"     'Prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5813466\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5813474\">",
"    <span class=\"h2\">",
"     Bleeding risk assessment, prophylaxis, and active bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the foregoing discussion, it is evident that measuring bleeding risk is one of the most challenging areas in the clinical care of liver disease patients. Given the uncertain relationship between conventional tests and hemostasis, it is inevitable that prophylactic measures usually lack strong supportive evidence. Nonetheless, some guidance can be offered, as outlined in the following paragraphs.",
"   </p>",
"   <p>",
"    Platelet counts parallel thrombin production, with adequate production around levels of",
"    <span class=\"nowrap\">",
"     55,000/microL",
"    </span>",
"    and near normal production at levels closer to",
"    <span class=\"nowrap\">",
"     100,000/microL.",
"    </span>",
"    Therefore, it is reasonable to aim for platelet counts of at least",
"    <span class=\"nowrap\">",
"     55,000/microL",
"    </span>",
"    during moderate risk procedures or interventions and platelet counts closer to",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    in high risk situations or in the presence of active bleeding. (See",
"    <a class=\"local\" href=\"#H5858437\">",
"     'Platelet level and function'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of inter-laboratory variation and the limited relationship of the INR to parameters such as thrombin production, it is difficult to endorse a specific INR cutoff applicable to either risk reduction or intervention in patients with liver disease and active bleeding. With this in mind, and because of the adverse effects of plasma infusion on portal vein pressures and collateral vessel flow, caution is warranted in the use of plasma. A judicial approach is further supported by the very limited effect of the traditional dose of two units of plasma, as this dose is unlikely to significantly alter coagulation factor levels.",
"   </p>",
"   <p>",
"    An alternative approach in high risk or actively bleeding cases is to measure fibrinogen levels and replace with cryoprecipitate for fibrinogen levels less than 120 to 150",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    This avoids the use of large volumes associated with plasma infusion. Raising fibrinogen increases the likelihood that a &ldquo;rescue&rdquo; agent such as rFVIIa would be effective should there be uncontrollable hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H11520860#H11520860\">",
"     \"Disorders of fibrinogen\", section on 'Cryoprecipitate and FFP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H4#H4\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Conditions affecting rFVIIa activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other general measures include maintaining the hematocrit at 25 percent or more, controlling infection, and treating uremia to minimize platelet dysfunction. Whether or not measurement of other factors such as factor VIII or protein C and whether thromboelastography (TEG) in the clinical setting are helpful remain to be determined.",
"   </p>",
"   <p>",
"    A high index of suspicion for hyperfibrinolysis (eg, delayed but persistent oozing from puncture wounds or dental work), supported where possible by laboratory studies such as TEG or clot lysis times, should be maintained because of the potential efficacy of anti-fibrinolytic agents in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=see_link&amp;anchor=H26#H26\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'Laboratory diagnosis of abnormal fibrinolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=see_link&amp;anchor=H31#H31\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'Treatment of abnormal fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5813490\">",
"    <span class=\"h2\">",
"     Risk assessment when thrombosis is present",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clear guidelines to guide treatment of venous thromboembolism (VTE) in patients with liver disease. Aggressive intervention in this setting carries some risk for bleeding that is difficult to measure because of the underlying liver disease and the effects of anticoagulation on the conventional INR.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    therapy and prophylactic strategies may also be blunted due to diminished levels of anti-thrombin.",
"   </p>",
"   <p>",
"    After the diagnosis of an episode of VTE, we recommend determining if the patient is at high risk for the development of gastrointestinal bleeding. This is accomplished via a screening endoscopy for gastric or esophageal varices.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the presence of varices, the patient is deemed high risk for anticoagulation. For those with peripheral deep vein thrombosis, placement of a vena caval filter (although controversial) is one option in order to balance these opposing problems.",
"     </li>",
"     <li>",
"      If the INR is elevated, there is no accurate reference range to guide traditional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy. This should entail discussion with the patient and hematology service to determine the proper course of anticoagulation with a non-warfarin-based regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5858570\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606165548\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental problem underlying the coagulopathy in patients with liver disease is a lack of protein production by the poorly functioning liver. A number of factors should be kept in mind when dealing with such patients. (See",
"    <a class=\"local\" href=\"#H525348817\">",
"     'Problem overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because both procoagulant and anticoagulant proteins are diminished in unpredictable ratios, the predilection for either bleeding or clotting in an individual patient is not predictable with current testing paradigms.",
"     </li>",
"     <li>",
"      Traditional measures of coagulation based on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (eg, use of the prothrombin time, INR, activated partial thromboplastin time) do not generally apply to the coagulopathy of liver disease. These tests should not be the sole source of information in predicting bleeding events, especially post-procedural complications.",
"     </li>",
"     <li>",
"      The use of traditional blood products (eg, fresh frozen plasma, plasma concentrates) is not helpful in reversing the coagulopathy of liver disease for more than a transient period of time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606165555\">",
"    <span class=\"h2\">",
"     Diagnosing the problem",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following battery of tests is helpful in determining the coagulation status of the patient with liver disease. (See",
"    <a class=\"local\" href=\"#H5858414\">",
"     'Tests of coagulation in liver disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"     </li>",
"     <li>",
"      Prothrombin time",
"     </li>",
"     <li>",
"      Activated partial thromboplastin time",
"     </li>",
"     <li>",
"      Thrombin time",
"     </li>",
"     <li>",
"      Fibrinogen level",
"     </li>",
"     <li>",
"      Fibrin D-dimer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement of individual coagulation factors (eg, factors V, VII, VIII) may be helpful in determining vitamin K status as well as the presence or absence of disseminated intravascular coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624493863\">",
"    <span class=\"h2\">",
"     Treatment of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of therapeutic options are available for the patient with liver disease and bleeding. However, none has been adequately studied. The proper treatment requires answers to the following questions. (See",
"    <a class=\"local\" href=\"#H5858365\">",
"     'Hypocoagulability in cirrhosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5858486\">",
"     'Therapeutic agents for bleeding'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5813474\">",
"     'Bleeding risk assessment, prophylaxis, and active bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is vitamin K deficiency present",
"     </li>",
"     <li>",
"      Is disseminated intravascular coagulation present",
"     </li>",
"     <li>",
"      Is the platelet count adequate",
"     </li>",
"     <li>",
"      What is the status of fibrinogen (level and function) and is fibrinolysis present",
"     </li>",
"     <li>",
"      Is there danger of volume overload if fresh frozen plasma is used",
"     </li>",
"     <li>",
"      Is there oral mucosal bleeding which can be corrected via the use of antifibrinolytic agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624493899\">",
"    <span class=\"h2\">",
"     Prevention and treatment of thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic or therapeutic anticoagulation and the use of antiplatelet agents are difficult issues to deal with in patients with liver disease, especially since the usual coagulation tests do not adequately assess thrombotic risk in these patients, who are also prone to develop treatment-associated bleeding. This area has also not been well studied, although the cautious use of unfractionated or low molecular weight heparins, with monitoring via measurement of anti-factor Xa levels, is worthy of consideration. (See",
"    <a class=\"local\" href=\"#H5813490\">",
"     'Risk assessment when thrombosis is present'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/1\">",
"      Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/2\">",
"      Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/3\">",
"      Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/4\">",
"      Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/5\">",
"      Dabbagh O, Oza A, Prakash S, et al. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/6\">",
"      Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/7\">",
"      Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/8\">",
"      Monroe DM, Hoffman M. The coagulation cascade in cirrhosis. Clin Liver Dis 2009; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/9\">",
"      Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999; 44:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/10\">",
"      Kajihara M, Okazaki Y, Kato S, et al. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007; 22:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/11\">",
"      Tonda R, Gal&aacute;n AM, Pino M, et al. Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. J Hepatol 2003; 39:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/12\">",
"      Lisman T, Adelmeijer J, de Groot PG, et al. No evidence for an intrinsic platelet defect in patients with liver cirrhosis--studies under flow conditions. J Thromb Haemost 2006; 4:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/13\">",
"      Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/14\">",
"      Bernard B, Grang&eacute; JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/15\">",
"      Senzolo M, Coppell J, Cholongitas E, et al. The effects of glycosaminoglycans on coagulation: a thromboelastographic study. Blood Coagul Fibrinolysis 2007; 18:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/16\">",
"      McKee RF, Hodson S, Dawes J, et al. Plasma concentrations of endogenous heparinoids in portal hypertension. Gut 1992; 33:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/17\">",
"      Kujovich JL. Hemostatic defects in end stage liver disease. Crit Care Clin 2005; 21:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/18\">",
"      Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/19\">",
"      Bennani-Baiti N, Daw HA. Primary hyperfibrinolysis in liver disease: a critical review. Clin Adv Hematol Oncol 2011; 9:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/20\">",
"      Nair GB, Lajin M, Muslimani A. A cirrhotic patient with spontaneous intramuscular hematoma due to primary hyperfibrinolysis. Clin Adv Hematol Oncol 2011; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/21\">",
"      Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/22\">",
"      Agarwal S, Joyner KA Jr, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000; 95:3218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/23\">",
"      Porte RJ, Knot EA, Bontempo FA. Hemostasis in liver transplantation. Gastroenterology 1989; 97:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/24\">",
"      Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/25\">",
"      Saleh T, Matta F, Alali F, Stein PD. Venous thromboembolism with chronic liver disease. Am J Med 2011; 124:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/26\">",
"      Gatt A, Riddell A, Calvaruso V, et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/27\">",
"      Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992; 6:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/28\">",
"      Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/29\">",
"      Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/30\">",
"      Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/31\">",
"      Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost 2008; 6:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/32\">",
"      Northup PG. Hypercoagulation in liver disease. Clin Liver Dis 2009; 13:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/33\">",
"      Fimognari FL, Violi F. Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 2008; 3:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/34\">",
"      Bittencourt PL, Couto CA, Ribeiro DD. Portal vein thrombosis and budd-Chiari syndrome. Clin Liver Dis 2009; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/35\">",
"      Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/36\">",
"      Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/37\">",
"      Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/38\">",
"      Senzolo M, M Sartori T, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/39\">",
"      Villa E, Zecchini R, Marietta M, et al. Enoxaparin prevents portal vein thrombosis (PVT) and decompensation in advanced cirrhotic patients: Final report of a prospective randomized controlled trial (abstract 120). Hepatology 2011; 54:418a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/40\">",
"      Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis 2009; 13:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/41\">",
"      Stravitz RT, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/42\">",
"      Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/43\">",
"      Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/44\">",
"      Munoz SJ, Rajender Reddy K, Lee W, Acute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/45\">",
"      Tripodi A, Caldwell SH, Hoffman M, et al. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/46\">",
"      Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/47\">",
"      Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/48\">",
"      Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/49\">",
"      Trotter JF, Olson J, Lefkowitz J, et al. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007; 7:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/50\">",
"      Lisman T, van Leeuwen Y, Adelmeijer J, et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int 2008; 28:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/51\">",
"      Porte RJ, Lisman T, Tripodi A, et al. The International Normalized Ratio (INR) in the MELD score: problems and solutions. Am J Transplant 2010; 10:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/52\">",
"      Bellest L, Eschw&egrave;ge V, Poupon R, et al. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/53\">",
"      Tripodi A, Chantarangkul V, Primignani M, et al. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. J Hepatol 2009; 51:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/54\">",
"      Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/55\">",
"      Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/56\">",
"      Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002; 126:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/57\">",
"      Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth 1992; 69:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/58\">",
"      Shah NL, Xavier E, Northup PG, et al. The use of thromboelastography, platelets, and INR in a clinical model for bleeding risk in cirrhotic patients. Gastroenterology 2009; 136(5 Supp 1):A795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/59\">",
"      Viola F, Mauldin FW Jr, Lin-Schmidt X, et al. A novel ultrasound-based method to evaluate hemostatic function of whole blood. Clin Chim Acta 2010; 411:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/60\">",
"      Murad MH, Stubbs JR, Gandhi MJ, et al. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion 2010; 50:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/61\">",
"      Kravetz D, Bosch J, Arderiu M, et al. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology 1989; 9:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/62\">",
"      Casta&ntilde;eda B, Morales J, Lionetti R, et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001; 33:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/63\">",
"      Villanueva C, Ortiz J, Mi&ntilde;ana J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/64\">",
"      Youssef WI, Salazar F, Dasarathy S, et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003; 98:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/65\">",
"      Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/66\">",
"      Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/67\">",
"      Argo CK, Balogun RA. Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis 2009; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/68\">",
"      Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/69\">",
"      Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/70\">",
"      Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245.",
"     </a>",
"    </li>",
"    <li>",
"     Marti-Carvajal AJ, Perez-Requejo JL. Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease. Cochrane Database Syst Rev 2007:CD006007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/72\">",
"      Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006; 23:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/73\">",
"      Hu KQ, Yu AS, Tiyyagura L, et al. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/74\">",
"      Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/75\">",
"      L&oacute;pez P, Otaso JC, Alvarez D, et al. Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis. Acta Gastroenterol Latinoam 1997; 27:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/76\">",
"      Agnelli G, Parise P, Levi M, et al. Effects of desmopressin on hemostasis in patients with liver cirrhosis. Haemostasis 1995; 25:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/77\">",
"      Stanca CM, Montazem AH, Lawal A, et al. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg 2010; 68:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/78\">",
"      Shah NL, Xavier E, Caldwell SH. Pro-coagulant blood product usage in liver disease patients. J Hepatol 2009; 50:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/79\">",
"      Gulley D, Teal E, Suvannasankha A, et al. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/80\">",
"      Lesmana CR, Inggriani S, Cahyadinata L, Lesmana LA. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition? Hepatol Int 2010; 4:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/81\">",
"      S&oslash;gaard KK, Horv&aacute;th-Puh&oacute; E, Gr&oslash;nbaek H, et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/82\">",
"      Intagliata N, Henry Z, Shah NL, et al. Prophylactic anticoagulation for deep venous thrombosis in hospitalized cirrhosis patients is safe and does not lead to increased bleeding events (abstract 1894). Hepatology 2011; 54:1253A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/83\">",
"      Lisman T, Porte RJ. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int 2011; 31:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/84\">",
"      Northup PG, Intagliata NM. Anticoagulation in cirrhosis patients: what don't we know? Liver Int 2011; 31:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/85\">",
"      Senzolo M, Rodriguez-Castro KI, Rossetto V, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/86\">",
"      Bechmann LP, Sichau M, Wichert M, et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/7/33914/abstract/87\">",
"      Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13932 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33914=[""].join("\n");
var outline_f33_7_33914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5858570\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858358\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H525348817\">",
"      PROBLEM OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858365\">",
"      HYPOCOAGULABILITY IN CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525348894\">",
"      Abnormalities of platelet number and function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858372\">",
"      Infection and endogenous heparinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858379\">",
"      Hyperfibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858386\">",
"      HYPERCOAGULABILITY IN CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858393\">",
"      Portal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23501878\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23501885\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858400\">",
"      COAGULOPATHY IN ACUTE LIVER FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858414\">",
"      TESTS OF COAGULATION IN LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858423\">",
"      Prothrombin time (PT) and the International Normalized Ratio (INR)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5858430\">",
"      - INR variation in liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858437\">",
"      Platelet level and function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5858444\">",
"      - Bleeding time in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858451\">",
"      Fibrinogen and individual factor levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858458\">",
"      Fibrin degradation products and D-dimer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858465\">",
"      Fibrinogen abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3539444\">",
"      Thrombin generation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858472\">",
"      Thromboelastography and thromboelastometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858479\">",
"      Sonorheometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858486\">",
"      THERAPEUTIC AGENTS FOR BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858493\">",
"      Vitamin K",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858500\">",
"      Fresh frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858507\">",
"      Cryoprecipitate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858514\">",
"      Platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858521\">",
"      Recombinant factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858528\">",
"      Anti-fibrinolytics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858535\">",
"      Prothrombin complex concentrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858542\">",
"      Desmopressin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525349129\">",
"      Blood product usage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858549\">",
"      Renal support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858556\">",
"      VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5858563\">",
"      Anti-platelet and anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5813466\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5813474\">",
"      Bleeding risk assessment, prophylaxis, and active bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5813490\">",
"      Risk assessment when thrombosis is present",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5858570\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606165548\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606165555\">",
"      Diagnosing the problem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624493863\">",
"      Treatment of bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624493899\">",
"      Prevention and treatment of thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/13932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13932|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/24/7566\" title=\"figure 1\">",
"      Splenic platelet pooling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/37/16991\" title=\"figure 2\">",
"      Primary hyperfibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/38/9836\" title=\"table 1\">",
"      Properties of coagulation factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3993?source=related_link\">",
"      Extrahepatic portal vein obstruction (portal vein thrombosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_7_33915="Automatic external defibrillator use in children";
var content_f33_7_33915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key points regarding the use of Automatic External Defibrillators (AED) in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        &bull; VF is the initial rhythm in 9 to 19 percent of children experiencing out-of-hospital cardiac arrests.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Survival with VF is better than survival with asystole.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Defibrillation is indicated for the treatment of VF and pulseless VT.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; AEDs are computerized machines that automatically diagnose VF and use voice prompts to instruct rescuers to",
"        <strong>",
"         defibrillate",
"        </strong>",
"        , if appropriate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; AEDs have demonstrated both high sensitivity in detecting VF and high specificity in identifying nonshockale rhythms in children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For infants and children with VF or pulseless VT, shock delivery may be accomplished by the following devices (in order of preference):",
"        <br/>",
"        <ol>",
"         <li>",
"          Manual defibrillator (when used by a trained provider)",
"         </li>",
"         <li>",
"          AED with a dose attenutation device",
"         </li>",
"         <li>",
"          AED without a dose attenuation device",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For in-hospital defibrillation, there are no data comparing manual defibrillators with AEDs or clear guidelines specifying the use of one over the other.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; AEDs cannot be used for cardioversion.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VF: ventricular fibrillation; VT: ventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33915=[""].join("\n");
var outline_f33_7_33915=null;
var title_f33_7_33916="Maternal fetal thrombocytopenia";
var content_f33_7_33916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of maternal and fetal thrombocytopenia in 15,471 consecutive women admitted for labor and delivery, 1986-1992",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mother's health status (percent of all 15,471 women)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maternal platelet count &lt;150,000/&micro;L (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infant platelet count at birth &lt;50,000/&micro;L (percent of births to women with platelet counts &lt;150,000)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infant platelet count at birth &lt;50,000/&micro;L (percent of births to all women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal - 13,925 (90 percent)",
"       </td>",
"       <td>",
"        756 (5 percent)*",
"       </td>",
"       <td>",
"        1 (0.13 percent)",
"       </td>",
"       <td>",
"        1 (0.01 percent)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia - 1414 (9 percent)",
"       </td>",
"       <td>",
"        216 (15 percent)",
"       </td>",
"       <td>",
"        4 (1.9 percent)",
"       </td>",
"       <td>",
"        5 (0.35 percent)&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ITP - 46 (0.3 percent)",
"       </td>",
"       <td>",
"        31 (67 percent)",
"       </td>",
"       <td>",
"        2 (6.5 percent)",
"       </td>",
"       <td>",
"        4 (8.7 percent)&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus - 55 (0.4 percent)",
"       </td>",
"       <td>",
"        8 (15 percent)",
"       </td>",
"       <td>",
"        Zero",
"       </td>",
"       <td>",
"        Zero",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At risk for neonatal alloimmune thrombocytopenia - 18 (0.1 percent)&loz;",
"       </td>",
"       <td>",
"        3 (17 percent)",
"       </td>",
"       <td>",
"        3 (100 percent)",
"       </td>",
"       <td>",
"        9 (50 percent)&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other hematologic and medical disorders - 13 (0.1 percent)&sect;",
"       </td>",
"       <td>",
"        13 (100 percent)",
"       </td>",
"       <td>",
"        Zero",
"       </td>",
"       <td>",
"        Zero",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Two-thirds of these thrombocytopenic mothers had platelet counts of 130,000-150,000/&micro;L. The one infant had trisomy 21 and congenital marrow dysplasia.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      All five infants were premature and delivered by Cesarian section; one had trisomy 13; three had birth weights &lt;10th percentile for gestational age (two of three had intracranial hemorrhage); one was normal birth weight for gestational age.",
"      <br>",
"       &Delta; Platelet counts in these four infants were 20,000-49,000/&micro;L. None had clinically important bleeding.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        These 18 women had maternal-paternal platelet alloantigen mismatch diagnosed because of a previous thrombocytopenic fetus (15) or were sisters of women who had infants with alloimmune thrombocytopenia. Six of nine infants had platelet counts &lt;20,000/&micro;L and these were the only infants in this study with platelet counts &lt;20,000/&micro;L had intracranial hemorrhage in utero; one died. The thrombocytopenia in the three mothers was assumed to be the incidental thrombocytopenia of pregnancy.",
"        <br>",
"         &sect; Women with other hematologic or medical disorders, not further specified.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Burrows RF, Kelton JG, N Engl J Med 1993; 329:1463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33916=[""].join("\n");
var outline_f33_7_33916=null;
var title_f33_7_33917="Factors associated with CRC";
var content_f33_7_33917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factors associated with annual new cases of colorectal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sporadic: men and women age 50 and older with no special risk factors; IBD: inflammatory bowel disease; FAP: familial adenomatous polyposis; HNPCC: hereditary nonpolyposis colorectal cancer; FH: positive family history; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. J Natl Cancer Inst 1991; 83:243.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33917=[""].join("\n");
var outline_f33_7_33917=null;
var title_f33_7_33918="Arteriovenous anastomosis postablation 2";
var content_f33_7_33918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous anastomosis postablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ablated area between the recipient vein and donor artery. The laser fiber is at 12 o'clock.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD and Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33918=[""].join("\n");
var outline_f33_7_33918=null;
var title_f33_7_33919="Parotid gland PI";
var content_f33_7_33919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parotid gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parotid gland makes saliva, which flows into the&nbsp;mouth through a thin tube called the parotid duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_7_33919=[""].join("\n");
var outline_f33_7_33919=null;
